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Abstract 
Factors that contribute to drug addiction have been investigated extensively in recent 
years. In the past, environmental factors such as stress, peer group influence and drug 
availability were thought to be major contributors to addictive behaviour. More 
recently, through a number of twin and adoption studies, it was shown that genetic 
factors are also involved. It was shown that there was an 8-fold increased risk of drug 
disorders among the relatives of probands who abuse alcohol or other range of 
addictive substances like opioids and cocaine. Furthermore, a high~r concordance rate 
for drug abuse was reported in monozygotic twins than in dizygotic twins. These 
findings encourage the exploration of genetic factors that cause addiction. As a result, 
most scientists have investigated the mesocorticolimbic pathway, which mainly 
consists of nucleus accumbens (NAc) and ventral tegmental area (VTA). These two 
regions of the brain may be the important part in the behavioral reward and 
reinforcement. In addiction, it was suggested that the dopaminergic, opioidergic and 
·GABAergic systems participated in drug reward. 
It was noted that the mu opioid receptor is the primary site of opiate action. Recent 
studies showed that the activation of mu opioid receptors in the VTA causes inhibition 
of GABA interneurons, in turn, it reduces the inhibition of the dopaminergic neurons. 
Ultimately, excitation of dopamine terminals is resulted. A number of association 
studies showed that there is an association between the TaqI Al allele of D2 
dopamine (DRD2) receptor gene, allele 9 of dopamine transporter (DAT) gene, 
gamma 2 subunit of GABA A (GABRG2) receptor gene and addictive behaviour like 
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alcoholism, cocaine dependence and gambling. Recently, it was shown that the 
A118G mutation site of the mu opioid receptor (MOR) gene and a polymorphism at 
the delta opioid receptor (DOR) gene may be associated with opioid dependence. 
Taken together, it is worth examining whether there is any association between heroin 
dependence and genes of the mesocorticolimbic pathway. This study involved using 
restriction fragment length polymorphism and denaturing HPLC (dHPLC) for 
genotyping DNA samples obtained from the heroin addicts in the Hong Kong Chinese 
population. In Hong Kong, approximately 87% of reported addicts are heroin abusers. 
An association was investigated involving the polymorphisms of the MOR exon 1 and 
intron 2，DOR exon 3’ DRD2, DAT and GABRG2 genes. 
In addition, the addiction severity index (ASI) was obtained for each heroin-
dependent subject. The ASI examined the medical, employment, drug, legal, 
family/social relationships and psychiatry status of each subject, in order to assess the 
environmental factors that are associated with heroin dependence. 
Results from the present study showed that the polymorphisms of A l l8G of exon 1 
and C1031G of intron 2 of the human mu opioid receptor (hMOR) gene and the 
polymorphism of T921C of exon 3 of the human delta opioid receptor (hDOR) gene 
are significantly associated with heroin dependence. In addition, when an individual is 
found to carry a double dose of the variant gene, the vulnerability of heroin 
dependence is more robust as compared with those who carries a zero or single dose 
of the variant gene. Furthermore, the G allele of A118G and C1031G polymorphisms 
. o f the hMOR gene and the C allele of T921C polymorphism of the hDOR gene are 
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shown to favour heroin dependence. 
The present results also showed that no significant association was found for the 
DRD2, DAT as well as the GABRG2 genes. Therefore, it maybe concluded that the 
polymorphism of mu and delta opioid receptor genes may contribute to the 
. vulnerability of heroin dependence. 
When the factors of the ASI were analyzed using the Pearson's correlation, a 
significant association was found in 3 (medical, employment .and family/social 
relationships) out of 5 (medical, employment, drug, legal and family/social 
relationships) factors in the AS!. They were found to be correlated with psychiatric 
problems but not with drug problems. It seems therefore that environmental factors 
mainly affect the psychiatry status of the heroin-dependent subjects and not directly 
the nature of heroin dependence. Some of these factors may be related to their poor 
educational standards since 96.5% of subjects attained an educational standard no 
higher than Form 3, thus contributing to them having employment problems. The lack 
of employment may precipitate psychiatric symptoms like depression, anxiety and 
tension, which may also affect the subjects' family/social relationships. It is 
interesting to observe that the ASI drug status is only correlated to legal status, which 
may be due to the frequent police charges that these subjects received for possession 
of drugs or drug paraphernalia. 
When genotype frequencies were correlated with the ASI, chi-square test showed 
statistical significant correlations between allelic frequencies and ASI factors between 
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G allele of the CI031G polymorphism and family/social relationships status as well as 
that of psychiatric status. Although the functional role of the hMOR and hDOR 
polymorphisms is still unclear, it may be possible that this polymorphism or other 
nearby mutation site which is in linkage disequilibrium with itself. Thus, this gene 
may play a role in the determination of personality or susceptibility to psychiatric 
disorders of these heroin-dependent subjects, which may in turn account for the poor 
relationships that they have with family members and in society. 
� 
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CHAPTER ONE INTRODUCTION 
1.1 Heroin 
Heroin (O，O -diacetylmorphine) is a common Schedule I semisynthetic drug. Street 
names associated with heroin include "smack", "H", "horse" and "junk". Heroin was 
named because of its heroic property (Pinger et al., 1998). Pure heroin is a white, 
crystalline, soluble powder with a bitter taste. A bag of 100 mg of heroin sold on the 
street is not pure. It is diluted with lactose, mannitol, dextrose, talc, milk powder or 
quinine at each level of distribution (Schwartz, 1998). Most illicit heroin varies in 
colour from white to dark brown because of impurities. 
Another form of heroin, known as "black tar", has also become readily available in 
Central American countries like Mexico and Guatemala. This dark Mexican heroin 
usually ranges from a dark brown powder to a black tar, which is the result of the 
crude processing methods used to illicitly manufacture heroin in a faster and simpler 
way (Bono, 1998). 
There are 3 common self-administration patterns of heroin. It can be smoked, snorted 
or injected. The latter is the most efficient way to take this drug. However, the most 
popular way of heroin administration in Hong Kong is the practice popularly referred 
to as "chasing the dragon" (Karch, 1996). The heroin powder is heated on a piece of 
tin foil over a flame and the user inhales the fume through a straw. The heroin is dyed 
. red and the upwardly curling fume resembles the tail of a dragon (Jenkins et al., 
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1994). 
1.1.1 Historical Background 
Opium is said to have been introduced to China as a medicinal trade item by the 
Arabs during the eighth-century T'ang dynasty, or perhaps a century before. Chinese 
edicts not only oppose the importation of opium but also limited all trade and this had 
been proliferating since the early eighteenth century. However this did not stop traders 
from evading the laws by bribery, by shipping to other ports or by smuggling. To 
suppress the opium trade, the emperor appointed Lin Tse-hau, Commissioner Lin, and 
gave him broad powers. In March 1839, Lin arrived in Canton and demanded the 
surrender of all the opium in the traders' possession as well as a guarantee that they 
would stop shipping opium. Unfortunately, this did not happen and continued ship 
seizures along with misunderstandings eventually led to the Opium Wars. Traders 
who refused to cease shipping opium to China provoked the first Opium War between 
China, Britain and other nations. The war lasted from 1839 until the signing of the 
Treaty of Nanking in 1842. By 1856, with piracy, opium smuggling and addiction at 
an all-time high, the Chinese were again desperate to end the trade. The Second 
Opium War declared by the British ended with another defeat for China. In 1858，the 
Treaty of Tientsin gave the foreigners even more freedom and power in opium trade. 
The West discovered that opium smoking could not be contained in distant colonies 
and that it had spread to Europe and North America, lending another facet to the 
world's growing drug problem (Hodgson, 1999). 
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In 1847, C.R Wright in London first synthesized heroin, one of the derivatives of 
opium. This process involved the boiling of anhydrous morphine with acetic 
anhydride and produced a series of acetylated morphine derivatives. One of the 
derivatives was diacetylmorphine (heroin) (Eddy, 1953). In 1898，Strube reported that 
heroin could be used in treatment for patients with tuberculosis and for relief of severe 
coughs without ill effects (Strube, 1898). In the same year in Germany, scientists at 
the Bayer Company, known for manufacturing aspirin, concluded that heroin 
produced less respiratory depression than codeine. Based on these findings, the Bayer 
Company started producing heroin commercially as a safer cough suppressant. 
Originally, heroin was considered a better analgesic than morphine, a more efficient 
cough suppressant and a non-addictive cure for morphine and opium withdrawal 
symptoms. However, 12 years later, it was revealed that heroin was at least as 
addictive as morphine (de Ridder, 1994). 
Since the establishment of the United States Pure Food and Drug Act of 1906, an 
accurate label is required on all drugs sold interstate, specifically referring to heroin, 
morphine, opium and cocaine (Pinger et al.’ 1998). In the 1920s, because of its higher 
potency and illicit availability, heroin addiction became a serious problem (Richard, 
1974). In view of this, the Narcotic Drug Import and Export Act of 1924 was 
amended in the United States to prohibit the importation of opium for the 
manufacturing of heroin. Meanwhile, heroin became available in the black market. 
One year later, the International Opium Convention limited the supply of heroin from 
Europe. Shortly thereafter, it was found that heroin was manufactured secretly in 
• China. (Bono,1998). Heroin abuse accelerated gradually in the 1960s when other 
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drugs, such as hallucinogens, became popular. In 1970，the Controlled Substances Act 
classified heroin as a Schedule I drug. This means that heroin is a drug susceptible to 
abuse and without any medical value at all (Richard, 1974). 
During most of the 1980s, the supply of heroin in the United States mainly came from 
Southwest Asia, Pakistan, Iran, Afghanistan and Lebanon. In the early 1990s, the 
high-purity Southwest Asian heroin dominated the United States heroin market 
especially on the East Coast of the United States. The primary sources of that heroin 
are the Golden Triangle countries of Thailand, Laos and Burma, the Golden Crescent 
countries of Iran, Afghanistan and Pakistan, Mexico and most recently Columbia 
(Pinger et al., 1998). Traditionally, the purity of heroin ranged from 1 to 10%, more 
recently heroin purity can reach 98%. Since 1990，the national average purity of 
heroin sold on the streets increased dramatically from 24 to 35.8% in 1993. Heroin 
with the highest purity came from South America, averaging 59.3%, followed by 
47.2，32.2 and 27.8% from Southwest Asia, Southeast Asia and Mexico respectively. 
In 1995，the estimated world production of opium was 3400 metric tons. More than 
half was produced in Southeast Asia (Thailand, Laos and Burma), 1100 tons in 
Southwest Asia (Afghanistan and Pakistan) and 60 tons in South America and Mexico 
(Karch, 1996). 
In Hong Kong, according to the Hong Kong Government Central Registry of Drug 
Abuse (CRDA) report, it was noted that throughout the past decade, heroin continued 
to be the most popular drug of abuse in Hong Kong. Of the 13,297 individuals 
• reported in 1989 who are substance abusers, 92.9% of those were reported to abuse 
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heroin. The percentage of heroin abusers among the reported addicts fluctuates 
between 92% and 94% from 1989 to 1994 (CRDA report 1989-1994, 1995). 
However, it was indicated that there is a decline in the predominance of heroin abuse 
in Hong Kong as other psychotropic substances such as amphetamine, cannabis, 
triazolam and cough medicine are emerging gradually. The percentage of reported 
heroin abusers dropped from 89.0 % in 1995 to 86.6% in 1999. 
1.1.2 Manufacturing of Heroin 
By chemically altering morphine that was derived from the opium poppy, heroin can 
be manufactured. Among the 6 genera in the Papaveraceae family, Papaver 
somniferum was commonly cultivated as the "opium" poppy. The poppy is an annual 
plant. Although it grows in almost any climate, the optimal condition for its 
cultivation is warm and temperate. 
Opium poppies show variations in height, colour, shape and the number of capsules 
on each plant. After the flowers have fallen off, the ripened capsule is cut, allowing 
the latex to run down inside the plant. It takes 8-14 hours for the latex to become 
solidified; by using a dull blade, the latex is scraped off the capsule. Morphine is the 
principal alkaloid found in crude opium (Anon, 1963 ). Codeine and thebaine are also 
significant alkaloids present in opium. Opium contains approximately 10 to 12% 
morphine and 0.5 to 1.0% codeine as well as many other alkaloids (Yagiela, 1998). 
� 
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1.1.3 Route of Administration and Absorption Rate 
Heroin can be self-administered by ingestion (placed under the tongue), inhalation 
such as smoking or snorting, as well as by intravenous, intramuscular or subcutaneous 
injection. 
Oral administration is a familiar way to introduce heroin into the body. After heroin is 
dissolved in the stomach, it is then carried to the intestine and absorbed through the 
intestinal mucosa by passive diffusion. However, the relative degree of contact with 
the mucosa determines the amount of uptake in each segment. Although it is a 
convenient and safe route and the orally taken heroin does not have to be sterilized, 
the abusers who use this route may experience occasional nausea and stomach distress 
(Yagiela, 1998). The absorption of an oral dose of heroin is poor and incomplete, 
since acids in the stomach may break it down, or because it binds to other contents in 
the digestive tract or is excreted in the faeces. Therefore, it is difficult to estimate the 
oral dosage of heroin (Pinger et al., 1998). 
Inhalation is an increasing popular method of drug administration, although snorting 
heroin is the usual way for those who begin heroin use. Heroin that is inhaled reaches 
the mucous lining of the nose and throat before being absorbed into the bloodstream 
and reaches the alveoli of the lungs easily and rapidly. This method avoids the 
unpredictability of administration through the gastrointestinal tract. Furthermore, it 
eliminates the pain and discomfort that is associated with the injection route. 
• However, inhalation may lead to irritation to the throat and lungs or deterioration of 
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their cell membranes (Pinger et al.，1998). 
Smoking of heroin has been a popular route of administration in Eastern culture. This 
practice is named “ Chasing the Dragon". Alternatively, the heroin powder can be 
smoked through the lighted end of a cigarette. Smokers usually tilt their head 
backwards to prevent the heroin from falling off the cigarette (Karch, 1996). 
Another administration pattern is the injection of heroin. This can be done 
intravenously, intramuscularly or subcutaneously. However, since the 1980s, most 
users prefer the intravenous route in which the injected heroin powder bypasses the 
body's defense layers (skin, mucous membrane, lining of the alimentary canal) and 
then reaches the bloodstream very rapidly (Pinger et al., 1998). Heroin powder is 
prepared in a spoon and was diluted in a little water. Then the powder is boiled over a 
match, candle or cigarette lighter for a few seconds. In turn, a piece of cotton is used 
to filter out the impurities before injection. Then, the user looks for the large vein in 
the arm to inject the heroin and the "rush" follows immediately (Richard, 1974). The 
peak concentration in blood is achieved within 1 to 5 minutes after intravenous 
injection (Jenkins et al., 1994), and 5 minutes after intranasal and intramuscular 
injection (Cone et al., 1993). However, this practice has several drawbacks. There is 
an increase risk of infection and transmission of a variety of diseases such as HIV and 
hepatitis B virus resulting from the use of unsterile needles (Pinger et al., 1998). 
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1.1.4 Metabolism of Heroin 
The lipophilic characteristics of heroin promote its passage through biological 
membranes like the blood brain barrier and subsequent access to the site of action at 
the brain's opioid receptors (Nutt, 1996). However, the biotransformation of heroin 
into its more hydrophilic metabolites is essential for the termination of its biological 
activity and the elimination of these compounds from the body. The metabolic 
conversion of heroin is an enzymatic reaction. In the liver, the cytochrome P450 
enzyme family localized in the microsomes of the endoplasmic reticulum is involved. 
Other organs with significant metabolic capacity including the kidneys, 
gastrointestinal tract, skin and lungs may also participate. Normally, a significant 
portion of a dose of heroin may be metabolized in either the liver or intestines before 
it reaches the bloodstream (Pratt and Taylor, 1990). 
The biotransformation reactions are classified as Phase I functionalization reactions 
and Phase II biosynthetic reaction. During Phase I, heroin is converted rapidly to 
biologically active metabolites, like 6-monoacetylmorphine and morphine, by the 
hydrolysis of ester or amide linkages (Benet et al., 1996). As a result, after morphine 
is formed, it will then be subjected to N-dealkylation. (Fischman and Hahn, 1978). 
Subsequently, normorphine is produced which to in turn enters Phase II’ conjugation 
reactions. As a result, the major metabolite of heroin, the 3-glucuronide of morphine 
and the minor quantities of morphine-6-glucuronide are formed (Benet et al., 1996). 
• Following intravenous infusion of 70mg of heroin to human volunteers, 45% of the 
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dose was found in urine 40 hours (h) later. This consists of 38% conjugated morphine, 
approximately 4% free morphine, 1% 6-monoacteylmorphine and 0.1% 
diacetylmorphine (Baselt and Cravey, 1995). Urinary elimination half-lives of 0.6, 4.4 
and 7.9 h were reported for 6-monoacteylmorphine, morphine and conjugated 
morphine respectively after administration of 6mg of heroin by the intramuscular 
route (Cone et al., 1991). 
1.1.5 Physical and Psychological Effects of Heroin 
Administration of heroin produces analgesia, euphoria, and drowsiness. However, 
heroin does not cause the slurring of speech to the degree that alcohol and barbiturates 
do. Moreover, heroin reduces the sensitivity of the brainstem to levels of carbon 
dioxide that may be building up in the body. When a higher dose is administered, 
breathing becomes irregular and slow (MMWR, 1989). Other undesirable effects 
include constipation, stimulation of vomiting and suppression of rapid eye movement 
(REM) sleep (Pinger et a l , 1995). 
Tolerance develops when the dosage of administration has to be increased in order to 
obtain the same effects as the initial dose. Symptoms of physical dependence on 
heroin appear with the abrupt termination of chronic heroin administration. The 
symptoms that appear after a period of abstinence are referred to as withdrawal 
syndromes. They include anxiety, restlessness, irritability, general body aches, 
insomnia, runny nose and eyes, perspiration, fever and chills, hot flushes, dilated 
. pupils, nausea, gagging, vomiting, diarrhea, increased heart rate, increased blood 
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pressure and abdominal and other muscle cramps (Piatt, 1986; Pinger et al., 1995). 
It must however be noted that the psychological effects of heroin vary with 
individuals. The acute effects of heroin use can be observed outwardly as a behavioral 
pattern of lethargy, lack of concern and inability to concentrate. Inwardly, abusers feel 
peaceful together with experiencing feelings of well-being and euphoria. In addition, 
for intravenous users, during the rush, sexual pleasures can be experienced. 
Nevertheless, these highs last only a short time and are followed by a period of 
increased anxiety. Because tolerance develops, evidence of craving can be observed. 
The abusers as a result will self-administer continual doses without the need for other 
natural rewards like food and water in order to enjoy the positive effects and avoid the 
aversive ones (Pinger et al., 1995). The emotions experienced range from mild 
feelings of pleasure or relief of tension through stronger emotional drives that can 
lead to persistent use, to changes in lifestyle and personal commitments, including 
keeping the company of those who are similarly involved with the drug (Pinger et al., 
1998). 
1.2 Opioid Receptors 
Opioid receptors are widely distributed throughout the central nervous system (CNS) 
and the peripheral nervous system (PNS). Several types of opioid receptors exist, they 
are mu, delta, kappa and sigma. Each has an unique pharmacological profile, 
anatomical distribution and function (Van Ree et al., 1999). However, only the mu, 
• delta and kappa opioid receptors have been cloned and widely studied. In the 1990s, 
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opioid receptors were isolated, purified, cloned, sequenced, and the three-dimensional 
structures modeled, first in laboratory animals and then in human beings (Thompson 
et a l , 1993; Knapp et al , 1995; Minami and Satoh, 1995). All opioid receptors belong 
to a superfamily of guanine nucleotide regulatory proteins (G-protein)-couple(l 
receptors, all of which possess seven membrane-spanning regions. All opioid 
receptors mediate their effects via the closely linked G-proteins as well as a variety of 
second-messenger systems such as adenylate cyclase, potassium (K+) and calcium 
(Ca2+) channels, and phospholipase C (Homanics et al., 1998). Each opioid receptor 
type is coded for by a distinct gene and is expressed through a specific messenger 
RNA (Atcheson and Lambert, 1994). The enkephalins (Hughes et al., 1975)， 
dynorphins (Goldstein et al., 1979) and beta-endorphin (P-endorphin) (Bradbury et 
al., 1975) were identified as endogenous peptide ligands for the opioid receptors. Both 
enkephalins and dynorphins are neurotransmitters in the brain involved in pain 
preception, cognitive functions, affective behaviours and locomotion (Simon, 1991). 
Delta opioid receptors (DOR) exhibit low affinity for dynorphin, but are highly 
sensitivity to enkephalin. Dynorphin A is very potent at kappa opioid receptors 
(KOR), but these receptors have low affinity for enkephalin. Mu opioid receptors 
(MOR) exhibit high affinity for enkephalin, whereas p-endorphin binds potently to 
both DOR and MOR but has relatively lower affinity at KOR (Delfs et al., 1994). 
1.2.1 Mu Opioid Receptors (MOR) 
MOR is the primary site for the�action f opioids including morphine, heroin, fentanyl 
and methadone. It has been classified into two subtypes, mu 1 and mu 2 according to 
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the relatively high and low binding affinity for opiate agonists such as naloxonazine 
and morphine respectively (Pasternak and Wood, 1986). In 1993, Chen and colleagues 
cloned cDNAs of the MOR from the rat brain. It was demonstrated that MOR possess 
a putative secondary structure of 7 transmembrane domains common to G-protein 
coupled receptors and display functional coupling to adenylyl cyclase (Chen et al.， 
1993). Subsequently, Wang et al. isolated an 18-kb genomic clone and showed by in 
situ hybridization that the human MOR gene (hMOR) mapped to chromosome 6q24-
q25 (Wang et al., 1994). 
MOR are present in both the brain and spinal cord. These receptors are widely 
distributed in the PNS and CNS. They are located in the superficial spinal cord, 
trigeminal nucleus caudalis, brainstem nuclei such as the chemoreceptor trigger zone, 
nucleus of the solitary tract, respiratory nuclei, cough center and related areas. They 
are also found in periaqueductal gray and periventricular zones of the midbrain, 
striatum, thalamus, amygdala, locus coeruleus neurons and nucleus accumbens 
(NAc). NAc is the region where the compulsive abuse of opioids, stimulants or drugs 
subject to compulsive abuse is implicated. However, there are few or no MOR in the 
cerebral cortex and cerebellum. 
The activation of MOR produce an inhibition of adenylate cyclase and a reduction of 
the level of cyclic adenosine 3',5'-monophosphate (cAMP) (Murthy and Makhlouf, 
1996). According to electrophysiological studies, its activation also opens K+ 
channels resulting in the hyperpolarization of gamma-aminobutyric acid (GABA) 
• interneurons. As a result, the dopaminergic neurons are released from the inhibition 
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by the GABA interneurons and in turn, the firing of dopaminergic neuron is increased 
and an increased release of DA resultes (Johnson and North, 1992). Studies on mu-
receptor knockout mice suggest that MOR may play a role in analgesia (Matthes et 
al.，1996; Sora et al., 1997), respiratory depression (Shook et a l , 1990)，meiosis, 
gastrointestinal motility (Kromer, 1988), euphoria, reward, withdrawal (Romanics et 
al” 1998) and immunosuppression (Bryant and Holaday, 1993). 
From genetic studies, five single-niicleotide polymorphisms (SNPs) in the coding 
region of the hMOR exon 1 have been identified (Wang et al； 1994; Mestek et al. 
1995; Bergen et al., 1997; Berrettini 1997; Bond et a l , 1998). The most prevalent 
SNP is a nucleotide substitution at position 118 (118A-G) of the coding region, 
predicting an amino acid change at a putative N-glycosylation site. The 118 A-G 
(A118G) variant receptor was found to bind p-endorphin approximately 3 times more 
tightly than the most common allelic form of the receptor. Furthermore, P-endorphin 
is approximately 3 times more potent at the A118G variant receptor. Therefore, the 
A118G polymorphism in hMOR gene may implicate a variation of vulnerability to 
develop addiction due to the different sensitivity to opioids (Bond et al., 1998). 
Smolka et al (1999) tested whether the A118G polymorphism is associated with a 
variation in central dopaminergic sensitivity during alcohol withdrawal in alcoholics. 
This study suggested that the A118G polymorphism modulates the central 
dopaminergic sensitivity during acute alcohol withdrawal. The apomorphine (APO)-
induced growth hormone (GH) response represents an indicator of central 
dopaminergic sensitivity. Results showed that there was a 2-fold higher APO-induced 
GH response one week after alcohol cessation in alcoholics carrying the A118G 
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variant as compared with those alcoholics with the wild-type genotype (Smolka et al., 
1999). It was postulated that the change in dopaminergic activity may also contribute 
to opioid dependence. 
A C17T variant was also found in the coding region of the hMOR gene exon 1. The 
C17T polymorphism changes an alanine residue to a valine residue. Although the 
C17T variant was present in higher proportion among 55 opioid-dependent subjects 
than the 51 controls, it was only at a marginal significance level (p=0.054) (Berrettini 
et al., 1997). In view of this result, it was suggested that further studies on 
polymorphisms at the hMOR genes are necessary for the investigation of association 
between opioid dependence and the hMOR gene. 
1.2.2 Kappa Opioid Receptors (KOR) 
High concentrations of KOR are found in the basal ganglia, NAc, ventral tegmental 
area (VTA), deep layers of the cerebral cortex, hypothalamus, periaqueductal gray and 
dorsal horn of the spinal cord. In 1995，Satoh and Minami hypothesized that KOR is 
synthesized and transported to the terminals of dopaminergic neurons and plays a role 
in reducing the release of dopamine (Minami and Satoh, 1995). Yasuda and 
coworkers mapped the human KOR (hKOR) gene to chromosome 8qll .2 by 
fluorescence in situ hybridization (Yasuda et al , 1994). The KOR resemble the MOR 
since they both possess a putative secondary structure of 7 transmembrane domains 
common to G protein-coupled receptors and affect the activity of the adenylyl cyclase. 
• The activation of the KOR reduces Ca^^ ion currents and increases K+ ion 
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conductance. Subsequently, there is an inhibition of neurotransmitter release. KOR 
are involved in analgesia (Pasternak, 1993), dysphoria, miosis (Dalman and O'Malley, 
1999)，some psychotomimetic effects such as disorientation and depersonalization 
feelings，and mild respiratory depression (Kumor et al” 1986). Although the function 
of KOR remains unclear, recent research indicated that the activation of the KOR 
antagonizes various MOR-mediated actions in the brain, including analgesia, 
tolerance，reward and memory processes (Pan, 1998). For instance, MOR facilitate 
dopamine release while dynorphin decreases dopamine levels (Donzanti et al., 1992). 
Moreover，it was shown that KOR can attenuate the acute behavioral effects of 
cocaine in rodents and can prevent the development of behavioral sensitization to 
cocaine as well as the decrease in self administration of cocaine (Heidbreder et al., 
1993; Negus et al” 1997). Due to this opposing action, KOR may be the target for the 
treatment of addiction (Shippenberg et a l , 1996). 
1.2.3 Delta Opioid Receptors (DOR) 
These receptors are involved in analgesia at the spinal and brain levels (Minami and 
Satoh’ 1995). However, the details of its pharmacological characterization are still 
under examination. DOR can be found in the NAc, the limbic system and the dorsal 
horn of the spinal cord. DOR may play a role in meiosis, analgesia at the dorsal horn 
and hypotension (Hirsch, 1996). The activation of DOR can inhibit adenylyl cyclase 
and modulate membrane conductance of C a � . and K+ (North et al., 1987; Childers， 
. 1 9 9 1 ) . The increase in K+ conductance and the decrease in Ca'^ conductance both 
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serve to reduce membrane excitability, control release of neurotransmitters, and thus 
may account for the analgesic properties of heroin (North et al., 1987; Chen et al., 
1993). 
Full-length transcripts of the DOR gene were discovered in the mouse brain and in no 
other tissues examined. Within the brain, the expression of the DOR gene is low. 
However, transcripts were found in particularly large amounts in the anterior pituitary 
and pineal glands (Evans et al, 1992). The abundant distribution of DOR in these 
regions suggests that they play a role in neuroendocrine function. Furthermore, the 
cloned DOR is targeted almost exclusively to axons (Dado et a l , 1993; Arvidsson et 
al. 1995) where it is most likely to function presynaptically (Glaum et a l , 1994). 
Befort and colleagues mapped the hDOR gene to chromosome lp34.3-36.1 by 
isotopic in situ hybridization and the homologous gene to mouse chromosome 4 
(Befort et al” 1994). Delta-selective agonists have been shown to modulate dopamine 
release in the NAc, thus affecting locomotor activity and self-administration 
behaviour (Devine and Wise, 1994). The antisense oligodeoxynucleotide to DOR 
attenuates morphine dependence in mice, suggesting that DOR may be involved in the 
development of morphine dependence and tolerance (Suzuki et al., 1994; Fundytus et 
al.，1995). An association between a T921C polymorphism of the DOR gene and 
heroin dependence in a German population has been reported (Mayer et al., 1997). It 
was suggested that the C allele could increase the risk for heroin dependence. 
However，the functional significance of this SNP has not been established. 
� 
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1.3 Dopamine Receptors 
Dopamine receptors can be classified into two main types, D I-like and D2-like. D 1-
like dopamine receptors consist of D 1 and DS dopamine receptors, which activate the 
enzyme adenylyl cyclase and increase intracellular levels of cAMP. D2-like dopamine 
receptors include D2, D3 and D4 dopamine receptors that inhibit adenylyl cyclase and 
decrease intracellular levels of cAMP (Kebabian and Calne, 1979). D2-like dopamine 
receptors also activate K+ channels and exert an inhibitiory influence on Ca2+ channel 
activities (Vallar and Meldolesi, 1989). Both D1- and D2-like dopamine receptors 
belong to a large superfamily of neurotransmitter and hormone receptors that are 
coupled to their specific effector functions via G-proteins (Dohlman et al., 1991). 
The D2 dopamine receptor (DRD2) has been implicated in many addiction behaviours 
such as alcoholism (Noble et al., 1998), nicotine dependence (Cornings et al., 1996) 
and cocaine dependence (Comings et al., 1994). DRD2 can be found in the caudate 
putamen, NAc and olfactory tubercle. In addition, DRD2 mRNA is found in the 
dopaminergic cell bodies within the substantia nigra pars compacta and VTA (Sibley 
and Monsma, 1992). 
The human DRD2 gene was cloned by Grandy et al in 1989. The DRD2 gene is 
localized to chromosome 11q22-23. The human DRD2 contains an additional 29 
amino acids in its putative third cytoplasmic loop as compared with the rat gene. The 
coding sequence is interrupted by 6 introns (Grandy et al., 1989). The DRD2 gene 
extends over 270 kb and an intron of approximately 250 kb separates the putative first 
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1.3 Dopamine Receptors 
Dopamine receptors can be classified into two main types, Dl-like and D2-like. Dl-
like dopamine receptors consist of D1 and D5 dopamine receptors, which activate the 
enzyme adenylyl cyclase and increase intracellular levels ofcAMP. D2-like dopamine 
receptors include D2, D3 and D4 dopamine receptors that inhibit adenylyl cyclase and 
decrease intracellular levels ofcAMP (Kebabian and Calne, 1979). D2-like dopamine 
receptors also activate K+ channels and exert an inhibitiory influence on Ca2+ channel 
activities (Vallar and Meldolesi, 1989). Both Dl- and D2-like dopamine receptors 
belong to a large superfamily of neurotransmitter and hormone receptors that are 
coupled to their specific effector functions via G-proteins (Dohlman et al., 1991). 
The D2 dopamine receptor (DRD2) has been implicated in many addiction behaviours 
such as alcoholism (Noble et al., 1998), nicotine dependence (Comings et al” 1996) 
and cocaine dependence (Comings et al., 1994). DRD2 can be found in the caudate 
putamen，NAc and olfactory tubercle. In addition, DRD2 mRNA is found in the 
dopaminergic cell bodies within the substantia nigra pars compacta and VTA (Sibley 
and Monsma, 1992). 
The human DRD2 gene was cloned by Grandy et al in 1989. The DRD2 gene is 
localized to chromosome llq22-23. The human DRD2 contains an additional 29 
amino acids in its putative third cytoplasmic loop as compared with the rat gene. The 
coding sequence is interrupted by 6 introns (Grandy et al.，1989). The DRD2 gene 
•extends over 270 kb and an intron of approximately 250 kb separates the putative first 
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exon from exons encoding the receptor protein (Eubanks et al., 1992). 
The contribution of the Al allele of DRD2 gene to alcoholism has been investigated 
extensively in recent years. In 1990，Blum's group demonstrated that there is an 
association between Al allele of the DRD2 gene and alcoholism. In a blinded study, 
Blum et al. showed that the presence of Al allele of the DRD2 gene correctly 
classified 77% of alcoholics, and its absence classified 72% of non-alcoholics. The 
polymorphic pattern of this receptor gene suggests that a gene that confers 
susceptibility to at least one form of alcoholism is located on the q22-q23 region of 
chromosome 11 (Blum et al , 1990). Although a number of studies did not replicate 
the association between DRD2 gene and alcoholism, at least seven independent meta-
analyses on a large number of Caucasian alcoholics and controls have confirmed a 
strong association of the Al allele of DRD2 gene with alcoholism (Berman and 
Noble，1997). Apart from Taql A polymorphism, a Taql B polymorphism being 
shown to be associated with alcoholism (Schuckit, 1986), and has also been shown to 
be associated with cocaine dependence (Noble et a l , 1993) and polysubstance abuse 
(Uhl et al., 1993). As a result, it was suggested that subjects with Al allele may 
compensate for the deficiency in their dopaminergic system by drinking alcohol and 
abusing drugs that are known to increase the brain's dopamine levels. 
Twins studies have reported that there is a higher concordance rate for alcoholism 
among monozygotic twins than in dizygotic twins (Pickens et al” 1991). Other 
evidence indicated that adopted children with alcoholic birth parents were four times 
more likely to become alcoholic than those adopted children with non-alcoholic birth 
.parents (Schuckit, 1986). These studies further showed that there is a strong genetic 
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factor that is associated with alcoholism and perhaps other substances of abuse. 
In animal studies, it was shown that the D2 receptor-deficient mice were akinetic and 
bradykinetic in behavioral tests and showed significantly reduced spontaneous 
movements (Baik et al., 1995). Maldonado and colleagues found that there was a 
suppression of rewarding behavior with morphine in DRD2 knock-out mice. But these 
knockout mice displayed normal response when food was used as a reward 
(Maldonado et al., 1997). 
Further to this, the long form of the D4 dopamine receptor (DRD4) exon III repeat 
polymorphism has been linked to novelty seeking personality traits (Ono et al., 1997) 
and opioid dependence (Kotler et al., 1997; Haim et al , 1998). The 7-repeat allele is 
significantly associated with the opioid dependence. Moreover, the personality trait of 
novelty seeking is also more pronounced in opioid abusers (Kotler et al., 1997). Based 
on these studies, further investigation into the association of dopamine receptor genes 
and opioid dependence is warranted. 
1.4 Dopamine Transporter (DAT) 
DAT acts to transport the released dopamine back into the presynaptic terminals for 
the next cycle. DAT is preferentially localized to the plasma membrane of medium-
small diameter dendrites that contain the catecholamine-synthesizing enzyme tyrosine 
hydroxylase (TH). These observations suggest that DAT may play a role in the 
removal of extracellular dopamine and psychostimulants that are bound to the 
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dendrites within the VTA and cortical and striatal axon terminals (Nirenberg et al , 
1997b). The expression of DAT is slightly lower in the prefrontal cortex than in the 
striatum (Sesack et al., 1998). However, it remains unclear whether the dopaminergic 
neurons in the VTA showed a difference in DAT expression. 
The involvement of DAT has been implicated in Parkinson disease, Tourette 
syndrome and cocaine and nicotine dependence. In 1992，the human DAT cDNA was 
cloned by Vandenbergh et al. and displayed a novel 40-base repetitive element with 
variable numbers of the repeat, ranging from 3 to 11 copies, in the 3-prime 
untranslated region (Vandenbergh et al., 1992). Animal studies demonstrated that the 
development of alcoholism is associated with the dopaminergic system in the striatum 
and the limbic system (Tiihonen et al., 1995). These authors showed that the striatal 
DAT density was markedly lower in non-violent alcoholics than in healthy controls, 
while slightly higher DAT densities were reported among violent alcoholics than 
controls. Thus svariants of the DAT gene may influence the vulnerability to 
alcoholism and other psychiatric diseases. 
In 1999, Lerman et al demonstrated that there was association of allele 9 of the DAT 
gene polymorphism between lack of smoking, late initiation of smoking and length of 
quitting attempts (Lerman et al , 1999). Furthermore, this polymorphism was also 
associated with low scores for novelty seeking which was suggested to be the most 
significant personality correlated with smoking cessation. It was also hypothesized 
that individuals that carried this polymorphism may have altered dopamine 
� 
transmission, which reduces their novelty and reward-seeking behaviours (Sabol et 
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al., 1999). 
1.5 Gamma-Aminobutyric Acid (GABA) Receptors 
GABA A (GABAA) receptors consist of 6 a forms ( a l , a2, a3, a4, a5, a6), 4 P 
forms (Pl，P2L，P2S, (33), 5 y forms (yl, ylL, ylS, 丫3，丫4)，16 form, Ixc form, le form 
and 3p forms (pl, p2, p3,) (Barnard et al” 1998). Heteropentamers with each subunit 
contribute to the wall of the central ion channel. Each subunit consists of a putative 
large N-terminal extracellular domain and 4 transmembrane domains with a large 
intracellular loop between the third and fourth membrane-spanning regions. The 
subunit combination of a 1(3272 constitutes the major GABAA receptor subtype in the 
brain (Olsen and Tobin, 1990). The GABAA receptor subunits share a low amino acid 
sequence homology with the subunits of the nicotinic acetylcholine receptors, 
although both of them are in the same superfamily of the transmitter-gated ion 
channels (Barnard, 1992). 
Benzodiazepines exerts their actions in the CNS through binding to the GABAA 
receptor complex. It was reproted that a y subunit was needed for a GABAA receptor 
isoform to interact with benzodiazepines to enhance GABA responses (Pritchett et al., 
1989). Moreover, the nature of the a subunit was also thought to determine the 
benzodiazepine site specificity (Wieland and Luddens, 1994). 
In 1992, the GABA receptor y2 subunit (GABRG2) gene was mapped to the 
immediate vicinity of the GABA receptor a l subunit (GABRAl) gene on the long 
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arm of chromosome 5 (Warrington et a l , 1992). These two genes were 6 cR apart on 
the radiation hybrid map. Wilcox et al. localized the y2 gene to 5q31.1-q33.2 (Wilcox 
et al., 1992). In the 丫2 knockout mice study, it was found that the y2 subunit serves no 
essential function for the assembly, transport and insertion into the cell membrane of 
the GABAA receptors. However, it is essential for the establishment of normal signal 
transduction characteristics and in single channel conductance (Gunther et a l , 1995). 
It has been reported that two novel polymorphisms in GABAA receptor (32 and a6 
subunit genes on human chromosome 5q33 were associated with alcohol dependence 
in a Scottish population. Although the Neil polymorphism at the GABRG2 gene was 
also examined, no significant association was found between this polymorphism and 
alcohol dependence in this Scottish population (Loh et al., 1999). Furthermore, a 
significant association was reported between GABAA receptor P3 subunit gene 
(GABRB3) and alcoholism in a Caucasian population. In addition, when the DRD2 
and the GABRB3 variants are combined, the risk for alcoholism is more robust than 
when these variants are considered separately (Noble et a l , 1998). 
1.6 Mesocorticolimbic Pathway 
Two major types of research paradigms have aided in the elucidation of the brain 
structures and neuronal tracts associated with reward. First, intracranial self-
stimulation (ICSS) experiments are widely used to study brain regions that appear to 
mediate reward. Secondly, physical or chemical lesions of specific brain areas have 
been utilized to study the influence of specific brain areas on drug self-administration 
behaviours (Niesink，1999). These studies have indicated that specific limbic 
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structures in the brain appear to be associated with the reward pathway of the brain 
(Wise，1990; Koob, 1992). The medial forebrain bundle, NAc, VTA, the lateral and 
ventromedial nuclei of the hypothalamus and the medial prefrontal cortex serve as 
core structures of the mesocorticolimbic pathway. Several other areas of the brain also 
provide input to the mesocorticolimbic pathway concerning emotional and 
motivational variables. These predominately limbic regions include the septum, 
amygdala and thalamus. Furthermore, other areas of the brain, which do not mediate 
reward, are involved in the translation of that experience into motor activity. For 
instance, the basal ganglia and cerebell画 are responsible for the control of fine 
voluntary and learned motor control when the reward pathway is stimulated (Niesink, 
1999). 
The cell bodies of the mesocorticolimbic system originate in the VTA and project to 
the NAc, septal region, amygdala, frontal cortex and olfactory tubercle (Van Ree et 
al” 1999). It was speculated that the hypothalamus is also mediated indirectly by 
components of the mesocorticolimbic pathway. Drugs of abuse are able either directly 
or indirectly to innervate the reward system to produce a reinforcing experience. For 
example，the reinforcing effects of heroin appear to be mediated in part by the VTA 
and NAc (Selfet al., 1995). 
The stimulation of dopamine transmission in the mesocorticolimbic system is a 
fundamental property of drug addiction. Lesions of the dopaminergic system of the 
mesocorticolimbic pathway reduce drug self-administration, most often without 
influencing other distinct drug effects such as effects on locomotion and the 
23 
development of tolerance or physical dependence (Spanagel and Weiss, 1999). Brain 
microdialysis studies reveal that drugs of abuse preferentially increase dopamine 
release in the limbic areas, especially the NAc (Johnson and North, 1992; Pontieri et 
al., 1995). Tthe reinforcing effects of opiates have been associated with dopaminergic 
neurons in the mesocorticolimbic pathway. Lesions of the VTA or the NAc reduce 
opiate reinforcement without influencing the development of tolerance. 
Microinjections of opiates into the VTA also produce conditioned place preference, 
which suggests that VTA may contribute to the reinforcement of opiates (Van Ree et 
al., 1999). 
Serotonergic neurotransmission in the medial forebrain bundle has also been found to 
influence the reward mechanism. Serotonin suppresses ICSS behaviour and 
serotonergic antagonists facilitate this behaviour (Niesink, 1999). The GABAergic 
system also potentiates reward. First the GABAergic and dopaminergic neurons 
exhibit significant interactions in the limbic system. GABA intemeurons in the VTA 
synapse with dopaminergic neurons, these GABAergic intemeurons normally serve to 
inhibit the firing of dopaminergic neurons. However, when morphine binds to the mu 
opioid receptors located on the GABAergic intemeurons and GABA release is 
inhibited, this produces a disinhibition of dopaminergic neurotransmission which in 
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1.6.1 Neural Substrates of Drug Reinforcement 
There is also a role for the mesocorticolimbic dopamine system in the priming effects 
of opiate and psychostimulant drugs on relapse of drug-seeking behavior. This system 
is therefore also a major neural substrate of drug-reinforcement (Wise and Bozarth, 
1987; Di Chiara and Imperato, 1988; Koob and Bloom, 1988). Morphine injections 
increase the firing of ventral tegmental dopamine neurons and thus increase the 
release of dopamine from nucleus accumbens terminals of the mesocorticolimbic 
dopamine system (Leone et al” 1991; Grant and Sonti, 1994). Moreover, these 
theories are consistent with several early studies which found that microinfusion of 
amphetamine directly into the NAc caused local dopamine release and reinstated 
heroin-seeking behaviour (Stewart and Vezina, 1988). Similarly, application of 
morphine directly into the VTA increases the release of dopamine in the NAc (Leone 
et al., 1991; Johnson & North，1992). However, injections of morphine into other 
brain regions rich in opiate receptors are ineffective. Further evidence has shown that 
dopamine is involved in relapse. Several studies have found that directly acting 
dopaminergic agonists are powerful inducers of both cocaine- and heroin-seeking 
behaviour (Wise et a l , 1990; Self et al , 1996). Conversely, the priming effects of 
heroin (Shaham and Stewart, 1996)，amphetamine (Ettenberg, 1990) and cocaine (Self 
et al., 1996), are blocked by the administration of dopamine antagonists. It is clear 
from these studies that drug-induced dopamine release in the NAc is both necessary 




1.6.2 Molecular and Cellular Basis of Addiction 
Addiction is a complex phenomenon with important psychosocial causes and 
consequences. However, it also involves a biological process. After a long period of 
drug exposure, the functioning of neurons are altered which in turn alters the 
functioning of the neural circuits where those neurons operate. Eventually, this leads 
to complex behaviours such as dependence, tolerance, sensitization and craving that 
are characteristics of the addicted state (Kreek, 1996; Wise, 1996; Koob and Le Moal, 
1997). 
The mechanism of the molecular adaptation of neurons to chronic opiate exposure has 
been well established. There is an up-regulation of the cAMP pathway in response to 
repeated opiate administration (Nestler, 1992; Nestler et aI., 1993). This up-regulation 
involves a rise in the concentrations of adenylyl cyclase, cAMP-dependent protein 
kinase A (PKA), and other components of this signaling pathway, including the DA 
synthesizing enzyme TH. Up-regulation of the cAMP pathway would oppose acute 
opiate inhibition of the pathway and also would represent a form of physiological 
tolerance. Upon removal of opiates, the up-regulated cAMP pathway would become 
fully functional and contribute to features of dependence as well as withdrawal 
(Sharma et aI., 1975; Collier, 1980; Nestler, 1992). 
There is direct evidence to support this model in the neurons of the locus coeruleus, 
the major noradrenergic nucleus in the brain. These neurons regulate attentional states 
and the activity of the autonomic nervous system and have been implicated in somatic 
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opiate withdrawal (Koob et a l , 1992; Maldonado, 1997). 
Acute opiate administration inhibits locus coeruleus neurons by increasing the 
conductance of an inwardly rectifying potassium channel through coupling with the 
Gi/o G-protein, as well as by reducing a sodium-dependent inward current through 
coupling with Gi/o protein. Consequently, the inhibition of adenylyl cyclase results. 
Reduced concentrations of cAMP decrease PKA activity and the phosphorylation of 
the responsible channel or pump is also affected. Inhibition of the cAMP pathway also 
decreases phosphorylation of numerous other proteins and in turn modifies many 
additional processes in the neuron. For instance, it reduces the phosphorylation state 
of cyclic AMP response-element binding protein (CREB)，one of the major cAMP-
regulated transcription factors in the brain, which may initiate some of the longer-
term changes in locus coeruleus function (Nestler and Aghajanian, 1997). 
In contrast to the acute administration of opiates, chronic administration of opiates in 
the locus coeruleus is caused by the up-regulation of the cAMP pathway (Nestler and 
Aghajanian, 1997). Chronic morphine increases concentrations of types I and VIII 
adenylyl cyclase (Matsuoka et al , 1994; Lane-Ladd et al.，1997), PKA catalytic and 
regulatory type II subunits and several phosphoproteins including CREB. As a result, 
the intrinsic excitability of locus coeruleus neurons is increased by enhanced activity 
of the cAMP cascade and the sodium-dependent inward current, which contributes to 
tolerance，dependence and withdrawal. The up-regulation of type VIII adenylyl 
cyclase is mediated by CREB (Nestler and Aghajanian, 1997). A reduction in CREB 
concentration, which is achieved by infusion of antisense oligonucleotides to CREB, 
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blocks the morphine-induced increase in this enzyme. In contrast, up-regulations of 
type I adenylyl cyclase and PKA subunits are not affected by this treatment. 
Accordingly, antisense oligonucleotide treatment partially attenuates the activation of 
locus coeruleus neurons seen during withdrawal, as well as the severity of certain 
opiate withdrawal behaviours (Lane-Ladd et al., 1997). This is consistent with the 
observation that mutant mice deficient in CREB showed attenuated opiate 
withdrawal. Experiments with transgenic mice have implicated the transcription factor 
CREB as being critical to the changes produced by chronic opioid treatment 
(Maldonado et al., 1996). Symptoms of opioid withdrawal are markedly reduced in 
mice missing two CREB proteins. 
In response to opiates, cells in the VTA and NAc also undergo plastic changes. 
Upregulation of the cAMP pathway occurs in neurons of the NAc in response to 
chronic administration of opiates, cocaine or alcohol (Terwilliger et al., 1991; 
Schoffelmeer et a l , 1996). However, it remains unclear which of several cell types 
within this region mediate this adaptation. There is preliminary evidence which 
implicates the cAMP pathway in the VTA (Bond and Williams, 1996; Tolliver et al., 
1996) and the periaqueductal gray, a brainstem region that contains major 
serotonergic nuclei, in opiate withdrawal (Jolas and Aghajanian, 1997). Biochemical 
and electrophysiological evidence suggests that chronic opiate exposure leads to an 
up-regulated cAMP pathway in these brain regions, specifically within the 
GABAergic neurons that innervate the dopaminergic and serotonergic cells (Bonci 
and Williams, 1996; Tolliver et aL，、1996; Jolas and Aghajanian, 1997). The up-
regulation of the cAMP pathway would lead to increased GABA release during 
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withdrawal and thereby to a reduction in the firing of dopaminergic and serotonergic 
neurons. The former could account for the reduction in dopaminergic 
neurotransmission from the VTA to the NAc that occurs during early phases of drug 
withdrawal. In addition, it is thought to contribute to associated aversive states such as 
stress and anxiety (Kuhar and Pilotte, 1996; Koob and Le Moal, 1997). 
Following continued drug reinforcement, a sustained increase in drug-seeking 
behaviour is exhibited by the individual for a prolong period when drug exposure has 
ceased. This persistent drug-craving behaviour may be caused by long-lasting 
adaptations in the brain's reward system. Chronic exposure to morphine, cocaine, or 
even alcohol, produces common intracellular biochemical adaptations in the VTA and 
NAc (Nestler, 1992; Nestler et al” 1993; Self et al., 1996). These adaptations consist 
of an increase in the level of TH in the VTA, and a decrease in the phosphorylation 
state of TH in the NAc (Beitner-Johnson and Nestler, 1991; Ortiz et a l , 1995). These 
adaptations are accompanied by decreases in the level of neurofilament (NF) proteins 
in the VTA (Beitner-Johnson et al” 1992). Furthermore, there is an up-regulation of 
glial fibrillary acidic protein (GFAP) in the VTA in the case of chronic morphine and 
ethanol exposure (Beitner-Johnson et a l , 1993; Ortiz et a l , 1995). 
1.6.3 Intracellular Substrates of Relapse 
Drug craving and relapse are triggered by dopaminergic activation of the D2 receptors 
on NAc neurons. D2 receptors inhibit adenylyl cyclase activity by coupling inhibitory 
G-proteins, leading to decreased levels of cAMR Reduced cAMP levels, in turn, 
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reduce the activity of PKA which otherwise would phosphorylate specific substrate 
proteins such as the voltage-gated neuronal sodium channels which are inactivated 
following repeated exposure to cocaine (White and Zhang, 1996). It is possible that 
these sodium channels are reactivated following acute inhibition of PKA activity (Li 
et a l , 1992; Schiffmann et al., 1995; Smith and Goldin, 1996) and this event 
contributes to relapse of cocaine-seeking behaviour. Eventually, D2 dopamine 
receptor activation could increase the excitability of D2-containing neurons within the 
NAc, an effect hypothesized to contribute to drug craving and relapse. On the 
contrary, Dl dopamine receptors could activate the cAMP pathway via G-proteins 
that stimulate adenylyl cyclase. Thus, Dl dopamine receptors modulate neuronal 
sodium channels via PKA-dependent phosphorylation (Li et a l , 1992; Schiffmann et 
al., 1995). PKA-mediated phosphorylation of neuronal sodium channels raises their 
threshold for activation, thereby reducing membrane excitability. This is one possible 
mechanism to explain the attenuation of cocaine priming produced by Dl agonists. 
1.7 Environmental Factors in Drug Addiction 
The availability of heroin on the street plays a vital role in the development of an 
individual's addiction. However, the availability of heroin alone is not enough to get a 
person induced to try the substance. Consider the historical cases of India and Turkey, 
where high quality opium was grown in abundance for years. Those societies never 
encountered the addiction problems of the nations they supplied. In the United States, 
although opiates were widely available to all population groups, some population 
gioups have had much higher addiction rates than others. Therefore, instead of 
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availability, it seems that personality, peer group pressure and social learning may 
contribute to making the individual more susceptible to heroin addiction (Zackon, 
1992; Hofler et al., 1999). Heroin users frequently demonstrate the kind of thinking 
and behaviour that psychiatrists call sociopathic. A sociopath is considered to lack the 
instincts that are essential for forming caring human relationships and is resistant to 
the lessons of experience (Brochu, 1997). Sociopaths are manipulative and devious, 
and always likely to blame others for the problems caused by their own behaviour 
(Zackon, 1992). One psychological condition widely seen in heroin addicts is low 
self-esteem (Hofler et al , 1999; Taylor, 2000). They believe that they-are a failure or 
are incompetent. They have feelings of hopelessness, and sometimes have 
psychological depression or schizophrenia. Some psychologists have said that heroin 
addicts suffer from hypophoria, a kind of depression that is specifically related to low 
self-esteem. Another common observation is that heroin addicts often seem to be 
strangely dependent on one family member or on the whole family for emotional 
support and acceptance, or develop an unusual attachment to a spouse or lover. Some 
theorists interpret this behaviour as signaling problems with individuation. This is a 
maturation process of establishing one's own sense of identity and one's capacity for 
independent choice and action. Since many addicts begin using drugs in their 
adolescence, one possibility is that a very troubled individuation process made them 
prone to use drugs like heroin to get immediate feelings of warmth and security. Many 
addicts confirm that when they began to use heroin they found that it gave them the 
feelings of security and confidence they lacked; that the drug made them feel able to 
handle inner conflicts, personal relationships and sexual intimacy (Zackon, 1992). 
Furthermore, stress and in particular emotional distress might increase the 
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development of opiate-self administration (Shaham et al” 1992; Shaham and Stewart, 
1994). 
Next to availability, the key social factor that determines whether a person will use 
drugs is the influence of peers. Drug availability often interacts with peer group 
pressure (Wong et al” 1997; Farrell and White, 1998). Users usually get their first 
drugs from their friends. Of course, not everyone follows the example of others, and 
often a young person will have several distinct peer groups with which to associate. 
Moreover, the apparent power of peer influence suggests to many social psychologists 
that addiction may have a social learning component. It is said that through social 
learning, less experienced peers are not just offered heroin or encouraged to use it, but 
are actually taught to use it and appreciate it. And through the example and approval 
of more experienced peer users, they leam the lifestyle of addiction. Therefore, social 
theorists as well as personality theorists view peer influence as a contributor to a 
propensity for using drugs (Zackon, 1992 ). 
1.8 Genetic Factors in Drug Addiction 
The etiology of drug abuse is a complex interplay of psychosocial and biological 
factors. Genetic factors also contributed to an individual's vulnerability to drug abuse. 
At present, there are no genes shown to be unique in causing drug abuse. Instead, 
there are genes that alter the normal function of the CNS as manifested by a wide 
range of interrelated impulsive, CGmpulsive, addictive, affective and anxiety 
behaviours (Comings, 1994; Comings et al” 1996). One of the outcomes or associated 
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behaviours, is the attempt to cope with these disorders through substance abuse. This 
means that the genetics of any one of these interrelated behaviours has relevance to 
drug abuse (Comings, 1996). 
One of the major players in vulnerability to drug abuse in human subjects is the brain 
reward system that is composed of dopaminergic neurons. Recently, the DRD2 
receptors were investigated in order to examine whether the variations in the 
prevalence of different forms of the DRD2 gene in drug addicts may participate in the 
susceptibility to drug addiction. The frequency of the Taql Al allele of DRD2 ine 
alcoholics (Noble, 1994; Blum et al., 1995; Noble et al., 1998)，cocaine abusers 
(OUara et al., 1993; Comings et al , 1994) and nicotine abusers (Noble et al., 1994; 
Coinings, 1996) has been compared with that of controls. It was found that the 
frequencies of the Al allele in the alcoholics, cocaine abusers and nicotine abusers 
were significantly higher than in controls. Noble and coworkers reported that in 57 
severe alcoholics, when compared to 45 controls, a significant increase was found in 
the prevalence (p=1.7xl0'^) and frequency (p=1.6xl0-^) of the DRD2 Al allele. 
Moreover, a significant progressive increase was observed in Al allele prevalence 
(p=3.1xlO"^) and frequency (p=2.7xl0"^) in the order of 45 controls, 114 less severe 
alcoholics and 57 severe alcoholics. In the same study, it was reported that the 
GABAA receptor [33 subunit gene was also involved in alcoholism. In 57 severe 
alcoholics, when compared with the 45 controls, a significant decrease was found in 
the prevalence (p=4.5xl0-^) and frequency (p=2.7xl0-') of the major G1 allele of the 
GABAB3 receptor. Moreover, a significant progressive decrease was noted in the G1 
allelic prevalence (p二2.4x10-3) and frequency (p=1.9xl0-^) in controls, less severe 
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alcoholics and severe alcoholics (Noble et a l , 1998). Furthermore, it has been 
reported that two novel polymorphisms in GABAA receptor (32 and a 6 subunit genes 
were associated with alcohol dependence in a Scottish population (Loh et al., 1999). 
Family, twin and adoption studies give the greatest source of information for 
examining the role of genetic factors in drug addiction, especially alcoholism. 
Merikangas and colleagues showed that there was an 8-fold increased risk of drug 
disorders among the first degree relatives of probands with drug disorders across a 
wide range of specific substances like opioids, cocaine, cannabis and alcohol. There 
was also evidence of specificity of familial aggregation of the predominant drug of 
abuse. Rates of abuse or dependence on hard drugs were greatest among the relatives 
of probands with opioid disorders (14.5%)，moderately elevated among relatives with 
cocaine or cannabis disorders (9.6% and 8.4% respectively) and lowest among 
relatives of probands with alcoholism (4.4%) when compared with relatives of 
controls (1.2%) (Merikangas et al” 1998). These findings supported the postulate that 
there may be some genes that predispose to drug abuse. Pickens and colleagues in a 
twin study of alcoholism showed a concordance rate among 114 male monozygotic 
twins of 63.4% versus 43.8% for dizygotic twins (p=0.05) (Pickens et al., 1991). 
Tsuang and colleagues studied 3372 male twin pairs from the Vietnam Era Twin 
Registry and showed that heroin abuse had the largest amount of unique genetic 
variance (38%) and the least amount of shared genetic variance (16%) when 
compared with other drugs like marijuana and amphetamines. It was concluded that 
heroin had a larger genetic influence unique to itself than any other drugs of abuse 
(Tsuang et a l , 1998). 
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From adoption studies, Goodwin and coworkers noted that the sons of alcoholics were 
about 4 times more likely to be alcoholics than sons of non-alcoholics and that being 
raised by either non-alcoholic adoptive parents or by biological parents did not affect 
this increased risk (Goodwin, 1979). In view of this, it was suggested that genetic 
factors influence the risk for alcohol and drug dependence. 
Recent evidence that demonstrated that genetic factors may have a role to play in 
heroin addiction came from association studies between the A118G polymorphism of 
the hMOR gene and opioid dependence (Bond et al , 1998). Another polymorphism of 
the C17T variant of hMOR was also found to be more prevalent among 55 opioid-
dependent subjects and 51 controls, although only at a marginal significance level 
(p=0.054) (Berrettini et al” 1997). The hDOR gene T921C polymorphism was also 
shown to be associated with heroin dependence in a German population (Mayer et al , 
1997). All this evidence suggests that individuals with various genetic compositions 
have different extents of vulnerability to substance abuse. 
1.9 Aim of Project 
The genetic contribution in addictive behaviours has been extensively investigated in 
recent years. Polymorphisms of receptor genes such as DRD2 (Lawford et al , 1997; 
Noble, 1998)，DRD4 (Kotler et al., 1997; Tomitaka et al., 1999)，GABA (Loh et al., 
1999), DAT (Lerman et al” 1999), hMOR (Berrettini et al., 1997; Bond et al., 1998) 
and hDOR (Mayer et al , 1997) have been shown to be associated with alcoholism, 
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cocaine dependence, nicotine dependence, heroin dependence or gambling in different 
populations. 
The aim of the present study was to explore if there is any association between a 
selected number of potential candidate gene polymorphisms and heroin dependence in 
the Hong Kong Chinese population. The advantage of an association study is that no 
assumption is made for the mode of inheritance, penetrance and age of onset of 
addictive behaviour. In the present study, a total of 200 heroin-dependent subjects 
were examined. The subjects were derived from two sources: heroin-dependent 
individuals who sought treatment at the Substance Abuse Clinic at the Prince of Wales 
Hospital，and heroin-dependent volunteers identified by snowball recruitment. All 
subjects were examined and assessed by a psychiatrist who specialized in substance 
abuse and all heroin-dependent subjects conformed to the criteria for opiate 
dependency as defined by DSM IV. Heroin-dependent subjects with a history of 
alcohol or substance dependence other than heroin were excluded from the study. 
Urine specimens obtained from each subject were analyzed to confirm heroin use and 
to exclude polysubstance abuse. A total of 97 control subjects were also used in this 
study. They were healthy blood donors at the Prince of Wales Hospital. Those who 
had a history of drug or alcohol dependence, smoking, gambling, or psychiatric 
illnesses were excluded. 
DNA was extracted from peripheral blood samples followed by genotyping using the 
restriction fragment length polymorphism and denaturing HPLC (dHPLC) methods. 
In this study, the A118G polymorphism at exon 1 of the hMOR gene, C1031G 
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polymorphism at intron 2 of the hMOR gene, T921C polymorphism at exon 3 of the 
hDOR gene, Taql A polymorphism of the DRD2 gene, 3’ VNTR polymorphism of the 
DAT gene as well as the GABRG2 gene were examined. Since ethnic variance exists 
for the A118G hMOR exon 1 polymorphism (Bond et al., 1998), the present study 
attempted to establish whether such ethnic variance also exists in the Chinese 
population. Nucleotide sequence information of intron 2 (NCBI Entrez NID: 
g2655102) revealed a C1031G polymorphism of the hMOR gene. Similarly, the delta 
opioid receptor has been implicated in the modulation of dopamine release in the NAc 
(Devine and Wise, 1994) and the development of morphine dependence and tolerance 
(Suzuki et al” 1994; Fundytus et al” 1995) Nucleotide sequence information for exon 
3 (NCBI Entrez NID: g497313) revealed a T921C polymorphism of the hDOR gene. 
Hence its role in heroin dependence was also investigated by Mayer et al. (1997). 
Since the Taql A polymorphism of the DRD2 gene, 3’ VNTR polymorphism of the 
DAT gene as well as the GABRG2 gene have been implicated in alcoholism and 
substance dependence, their role in heroin dependence in the Chinese population was 
also investigated. Any significant association between the polymorphisms of these 
candidate genes and heroin dependence was assessed using Yates chi-square test. The 
interaction between genotypes was also investigated by calculating the relative odds 
using logistic regression analysis. This analysis enabled the examination of a zero, a 
single or a double gene dosage of the variant gene that is carried by an individual, to 
assess the gene dosage of a variant gene affects the robustness of its vulnerability to 
heroin dependence. 
In .addition, all of the heroin-dependent subjects were interviewed, after training, 
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-using the Addiction Severity Index (ASI) questionnaire that covers medical, 
employment, drug, legal, family history, family/social relationships and psychiatric 
status. It can be used to rate the severity of a wide range of problems in the subject's 
life and suggest how these problems must be addressed if treatment is to be 
successful. In order to reveal if there is any correlation among the factors of ASI, 
Pearson's regression analysis followed by the chi-square test was used. In addition, 
the heroin-dependent subjects were divided into a less or more severe group based on 
their indices 0-4 or 5-9 respectively. This was to investigate whether any correlations 
may exist between variant allelic frequencies and individual factors of ASI. Results 
from this may help to draw a link between the genetic and environmental factors that 




CHAPTER TWO MATERIALS AND METHODS 
2.1 Recruitment of Subjects 
2.1.1 Heroin-dependent Subjects 
200 unrelated Chinese heroin-dependent abusers (185 males, 15 females) were 
recruited for this study. The patients were derived from two sources: the Substance 
Abuse Clinic at the Prince of Wales Hospital (PWH) (n=79) and snowball recruitment 
from The Society and Rehabilitation of Drug Abuse (n =121). 
2.1.1.1 Phenotype Assessment 
All patients were subjected to psychiatric assessment by the psychiatrist at the 
Substance Abuse Clinic at PWH using the Diagnostic and Statistical Manual IV 
(DSM IV) as the diagnostic instrument. DSM IV diagnostic criteria for substance 
abuse define a maladaptive pattern of substance use leading to clinically significant 
impairment or distress as manifested by three (or more) of the following, occurring at 
any time in the same 12-month period: i) Substance is often taken in larger amounts 
or over a longer period than intended; ii) Persistent desire or unsuccessful efforts to 
cut down or control substance use; iii) A great deal of time is spent in activities 
necessary to obtain the substance (e.g., visiting multiple doctors or travelling long 
distances), use the substance (e.g., chain smoking), or recover from its effects; iv) 
Important social, occupational, or recreational activities given up or reduced because 
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of substance abuse; v) Continued substance use despite knowledge of having a 
persistent or recurrent psychological or physical problem that is caused or exacerbated 
by the use of the substance. 
With regular heroin use, tolerance develops. This means the abuser must use more 
heroin to achieve the same intensity or effect. As higher doses are used over time, 
physical dependence and addiction develop. With physical dependence, the body has 
adapted to the presence of the drug and withdrawal symptoms may occur if use is 
reduced or stopped. Withdrawal, which in regular abusers may occur as early as a 
few hours after the last administration, produces drug craving, restlessness, muscle 
and bone pain, insomnia, diarrhea and vomiting, cold flashes with goose bumps ("cold 
turkey")，kicking movements ("kicking the habit"), and other symptoms. Major 
withdrawal symptoms peak between 48 and 72 hours after the last dose and subside 
after about a week. Sudden withdrawal by heavily dependent users who are in poor 
health is occasionally fatal, although heroin withdrawal is considered much less 
dangerous than alcohol or barbiturate withdrawal. 
Heroin-dependent patients were excluded if they had a history of alcohol or substance 
dependence other than heroin. Informed consent (written in Chinese) from all subjects 
was obtained prior to interview as well as blood and urine sample collection. 
2.1.1.2 Establishment of Socio-demographic Data 
� 
All subjects were interviewed using the Addiction Severity Index (ASI). ASI is a 
structured clinical interview for the collection of reliable and valid data on areas 
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related to drug addiction (Grant 1992). It can be used to rate the severity of a wide 
range of problems in the subject's life. The problems identified in the assessment do 
not necessarily relate to the problem of substance abuse, but must be addressed for 
treatment to be successful. ASI covers areas including medical, employment, drug, 
legal，family history, family/social relationships and psychiatric status (see Appendix 
I). Subjects were asked to rate how severe each problem has been in the last 30 days 
and whether they considered it important to seek treatment for the problem at the time 
of interview. The scale starts at 0’ meaning the subject is "not at all" bothered by the 
problem and ends at 4，meaning the subject is "extremely" troubled by the problem. 
The interviewer makes an independent assessment of the severity of each problem 
using a 10-point scale and calculates a severity rating. The scale starts at 0’ meaning 
no problem exists and treatment is probably not necessary and ends at 9，meaning an 
extreme problem exists and treatment is a must. The subject's score is then used to 
adjust slightly the interviewer's assessment of the severity of the problem (see 
Appendix II). The family history section was not given a severity index, but family 
history of alcohol-, drug- and psychiatric-related illnesses were recorded. The 
technology transfer package developed by the National Institute on Drug Abuse 
contains all the materials necessary for interviewers to conduct their own training. 
The material contains two training videotapes which demonstrate proper use of the 
ASI; a training facilitator's guide suggesting practice exercises; and a resource and 
scoring manual which provides instructions for calculating severity scores, 
interviewing tips, and an item-by-item discussion of the instrument. The ASI has been 
used in large research studies including the Drug Abuse Treatment Outcomes Study 
(DATOS) and the National Treatment Improvement Effectiveness Study (NTIES). 
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ASI gives highly consistent results when used by different interviewers and composite 
scores have proven effective in measuring treatment outcomes accurately. The 
severity ratings have the advantage of providing a readily understandable 10-point 
scale for representing a client's problems and need for treatment in each area covered 
by the interview. 
After the interview, a registered nurse and a medical officer collected a urine 
specimen and 6ml of blood sample respectively. The urine specimen was analyzed 
immediately using a urine kit (Triage ®Panel for Drug of Abuse, Biosite Diagnostics) 
to confirm heroin use and to exclude polysubstance use. 
2.1.2 Control Subjects 
A total of 97 control subjects (students, both academic and non-academic staff, 53 
males, 44 females) were recruited from PWH as well as The Chinese University of 
Hong Kong. They were healthy blood donors with no history of drug or alcohol 
dependence, smoking, gambling or psychiatric illness. 
2.2 DNA Extraction 
Blood was drawn from the peripheral vein of the subject and anticoagulated with 
EDTA. The blood samples were stored at -70°C before extraction. DNA was 
extracted from peripheral blood samples with the Viogene Blood and Tissue Genomic 
DNA Miniprep System (Viogene Catalog no. GGlOOl, USA). First of all, 200|il 
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blood sample was pipetted into a 1.5ml microcentrifuge tube. 20|al of 20mg尔 1 
proteinase K and 200^1 buffer EX were added to the sample. The mixture was mixed 
immediately by vortexing for 20 seconds (sec). Afterwards, the mixture was 
incubated at 60°C for 20 minutes (min) to lyse the cells. The sample was further 
incubated at 7 0 � C for 20 min to inactivate proteinase K. 210|il of isopropanol was 
then added to the sample and mixed by vortexing. After mixing, all the mixture was 
applied to the genomic DNA column (Viogene, USA) in a 2ml collection tube. The 
column，together with the 2ml collection tube, were centrifuged at 8000 rpm for 2 
min. The filtrate was decanted and the column was placed back to the collection tube. 
500叫 wash buffer was added to the column and was centrifuged again at 8000 rpm 
for 2 min. Then the column was placed into a new collection tube. Another 500^il of 
wash buffer was applied prior to further centrifugation at 8000 rpm for 2 min and at 
13000 rpm for a further 2 min to dry the column. The column was put into a new 
collection tube and DNA was eluted with 200|^1 of preheated ddH20 by centrifugation 
at 8000 rpm for 2 min. 
2.3 Genotyping 
2.3.1 A118G Polymorphism in Exon 1 of the Human MOR (hMOR) Gene 
The A118G polymorphism in exon 1 of the hMOR gene was analyzed using the 
restriction fragment length polymorphism (RFLP). The hMOR exon 1 RFLP was 
amplified using a forward primer: 5，-TCA GTA CCA TGG ACA GCA GC-3，and the 
reverse primer: 5，-GCA CAC GAT GGA GTA GAG GG-3，. 50 ng of purified DNA 
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was diluted into the PGR reaction mix consisting of PGR buffer (lOOmM Tris-HCl, 
pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCb) 1.5 mM MgOb， 
0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each forward and 
reverse primer and lU AmpliTaq Gold™ polymerase (Perkin Elmer Applied 
Biosystems, USA) in a total volume of 50^1. PGR was carried out in the thermal 
cycler (Perkin Elmer Applied Biosystems, Model no. PCR 9700，USA). The 
amplification steps were: i) denaturation at 94°C for 13 min, ii) 35 cycles of 
denaturation at 94�C for 45 sec, iii) annealing at 62�C for 30 sec, iv) synthesis at 72"C 
for 30 sec and v) final elongation at 72°C for 7 min. After 35 cycles, the PCR 
products were detected in a 2% agarose gel. PCR products were then loaded into a 96-
well plate and put into the WAVE™DNA Fragment Analysis System (Transgenomic, 
Inc.，USA) for genotyping. Denaturing HPLC (dHPLC) is a semi-automated method 
for detecting unknown DNA sequence variants. The sensitivity of the method is 
dependent on the temperature which is kept by the oven (Jones et al” 1999). The 
stationary phase consisted of 2[im nonporous alkylated poly-styrene divinylbenzyl 
(PS-DVB) micropellicular matrix packed into a 50 x 4.6 mm column (Huber, 1998). 
A 10^1 aliquot of each PCR product was then injected into the column and eluted at a 
flow rate of 0.9 ml/min with a mobile phase consisting of a mixture of buffer A and 
buffer B (Pirulli et a l , 2000). Buffer A consisted of 0.1 M/1 triethylammonium acetate 
(TEAA) solution, pH 7.0. Buffer B consisted of 0.1 M/1 TEAA containing 25% 
acetonitrile. The eluted DNA fragments were detected at 260 nm. Heterozygous 
species that are generated have a 1:1 ratio of wild-type and mutant DNA. A mixture 
of hetero- and homoduplexes can be yielded when the PCR product is hybridized by 
heating to 95°C and cooled down slowly. The base mismatch on the heteroduplex 
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formed a linear region of the single-stranded DNA that has been used to separate the 
two species and predict the mutation. At increasing temperatures, the DNA starts to 
melt selectively in the region of the base mismatch of the heteroduplexes. As a result, 
heteroduplex molecules were eluted before the homoduplexes, two peaks were then 
subsequently formed (see Fig 2 in Section 3.3). Genotyping was carried out without 
knowledge of the affected status. Prior to each run, 10|li1 of 209 mutation standards 
(Transgenomic, USA) was injected to ensure the optimal condition of the WAVE™ 
DNA Fragment Analysis System for mutation screening. 
2.3.2 C1031G Polymorphism in Intron 2 of the hMOR Gene 
20 ng purified DNA was diluted into the PGR reaction mix consisting of PCR buffer 
(lOOmM Tris-HCl, pH 8.8 at 2 5 �C ; 500ml KCl; 0.8% Nonidet P40 and 15mM 
MgCl)，1.5 mM MgCl2, 0.2 mM of each dNTP (dATP, dCTP, dGTP，dTTP), 25 pmol 
of each forward and reverse primer and lU Taq polymerase (MBI Fermentas, NY, 
USA) in a total volume of 25|aL The C1031G polymorphism was detected by an 
artificial Hinfl RFLP analysis. Using a modified forward primer: 5’-GCT CTG GTC 
AAG GCT AAG AAT-3，’ in which nucleotide 1027 (underlined) was changed from 
an A to a G, thereby an artificial Hinfl restriction site was generated. This was 
combined with the reverse primer: 5，-GTA AGA GAG TAG GTT GGA CCA-3，to 
amplify a 145bp PCR fragment. PCR was carried out in a thermal cycler (Perkin 
Elmer). The amplification steps were: i) denaturation at 9 4 � C for 5 min, ii) 35 cycles 
of denaturation at 94°C for 45 sec, iii) annealing at 62°C for 30 sec, iv) synthesis at 
7 2 � C for 45 sec and v) final elongation at 72�C for 7 min. 8|il of the 145 bp PCR 
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product was digested with 5U Hinfl (MBI Fermentas) restriction enzyme overnight at 
37° C. The restriction-digested products were resolved on a 5% agarose gel stained 
with ethidium bromide. The fragment lengths of the C allele were 124 and 21 bp, 
while the fragment length of the PGR product remained a 145 bp when the G allele 
was present. Heterozygous CG allele was indicated by the presence of both the 124 bp 
and 145 bp bands (see Fig. 10 in Section 3.4). 
2.3.3 T921C Polymorphism in Exon 3 of the Human DOR (hDOR) Gene 
20ng purified DNA was diluted into the PGR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 2 5 �C ; 500ml KCl; 0.8% Nonidet P40 and 15mM 
MgCl)，1.5 mM MgCl2, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP)，25 pmol 
of each forward and reverse primer and lU Taq polymerase (MBI Fermentas) in a 
total volume of 25^1. The T921C polymorphism was detected by an artificial BstEll 
RFLP analysis. Using a forward primer: 5'-TTC GTC ATC GTC TGG ACG CT-3’ 
and a modified reverse primer: 5'-GGT TGA GGC TGC TAT TGG GGT A-3' in 
which nucleotide 1158 (underlined) was changed from a C to a G，thereby an artificial 
B 遍 restriction site was generated. These two primers were combined to amplify a 
106bp PGR fragment. PGR was carried out in a thermal cycler (Perkin Elmer). The 
amplification steps were: i) denaturation at 94�C for 5 min, ii) 35 cycles of 
denaturation at 94�C for 45 sec, iii) annealing at 62�C for 45 sec, iv) synthesis at 72�C 
for 45 sec and v) final elongation at 72�C for 7 min. 8^1 of the 106 bp PGR product 
was digested with 5U BstEll (New England BioLabs Inc.) restriction enzyme 
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overnight at 60°C. The restriction digest products were resolved on a 5% agarose gel 
stained with ethidium bromide. The fragment length of the T allele was 89 bp, while 
the fragment length of the PGR product remained at 106 bp when the C allele was 
present. Heterozygotes TC were indicated by the presence of both the 89 and 106 bp 
bands (see Fig. 12 in Section 3.5). 
2.3.4 3'VNTR Polymorphism of DAT Gene 
Genotyping was performed on 83 controls and 161 heroin-dependent subjects. 50ng 
purified DNA was diluted into the PGR reaction mix consisting of PGR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
1.5 mM MgCl2, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of each 
forward and reverse primer and lU Taq polymerase (MBI Fermentas) in a total 
volume of 25|Lil. The 3' VNTR polymorphism of the DAT gene was detected by a 
RFLP analysis using a forward primer: 5'- TGT GGT GTA GGG AAC GGC CTG 
AG-3' and a reverse primer: 5' - CTT CCT GGA GGT CAC GGC TCA AGG-3'. 
PCR was carried out in a thermal cycler (Perkin Elmer). The amplification steps were: 
i) denaturation at 94�C for 5 min, ii) 30 cycles of denaturation at 9 4 � C for 30 sec, iii) 
annealing at 62°C for 30 sec, iv) synthesis at I T C for 30 sec and v) final elongation at 
72°C for 10 min. The size of PCR products ranged from 320bp to 520bp and these 
were resolved on a 4% agarose gel stained with ethidium bromide. The 6-repeat, 7-
repeat，9-repeat, 10-repeat and 11-repeat elements were represented by the band sizes 
320bp, 360bp, 440bp, 480bp and 520bp respectively (see Fig. 17). 
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2.3.5 Taql A Polymorphism of the DRD2 Gene 
Genotyping was performed on 89 controls and 174 heroin-dependent subjects. 50ng 
purified DNA was diluted into the PGR reaction mix consisting of PCR buffer 
(lOOmM Tris-HCl, pH 8.8 at 25�C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl)， 
1.5 mM MgCl2, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 25 pmol of 
each forward and reverse primer and lU Taq polymerase (MBI Fermentas) in a total 
volume of 30^1. The Taql A polymorphism was detected by RFLP analysis using a 
forward primer: 5'-GCT CTA TCT CCA ACT CTC ACA-3，，and a reverse primer: 
5，-AAG TCT ACT CAC CTC CAG GTA-3’ to amplify a 310bp PCR fragment. PCR 
was carried out in a thermal cycler (Perkin Elmer). The amplification steps were: i) 
denaturation at 94�C for 5 min, ii) 30 cycles of denaturation at 95�C for 30 sec, iii) 
annealing at 56�C for 30 sec, iv) synthesis at 72�C for 1 min and v) final elongation at 
720C for 10 min. lO^il of the 310 bp PCR product was digested with 5U Taql (MBI 
Fermentas) restriction enzyme for at least 8 hours (hr) at 65°C. The restriction-
digested products were resolved on a 2% agarose gel stained with ethidium bromide. 
The fragment lengths of the A2 allele were 180 and 130bp, while the fragment length 
of the PCR product remained at 310 bp when the Al allele was present. Heterozygous 
A1A2 allele was indicated by the presence of the 130 bp, 180bp and 310 bp bands. 
2.3.6 Neil Polymorphism of the GABRG2 Gene 
Genotyping was performed on 96 controls and 170 heroin-dependent subjects..20ng 
purified DNA was diluted into the PCR reaction mix consisting of PCR buffer 
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(lOOmM Tris-HCl, pH 8.8 at 25°C; 500ml KCl; 0.8% Nonidet P40 and 15mM MgCl), 
2.5 mM MgCb, 0.25 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 30 pmol of 
each forward and reverse primer and lU Taq polymerase (MBI Fermentas, USA, NY) 
in a total volume of 30|li1. The Neil polymorphism of GABRG2 was detected by an 
artificial Neil RFLP analysis. Using a modified forward primer: 5，-AGA AAT TTA 
CCA ACT GGT CTA GCC GG-3，in which nucleotide 3145 (underlined) was 
changed from an A to a C, thereby an artificial Neil restriction site was generated. The 
reverse primer was: 5'- AAA TCA AAT ATT GTG TCA TGC TTA GT-3'. These 
two primers were combined to amplify a 287bp PGR fragment. PGR was carried out 
in a thermal cycler (Perkin Elmer). The amplification steps were: i) denaturation at 
95�C for 4 min, ii) 40 cycles of denaturation at 95�C for 30 sec, iii) annealing at 50�C 
for 30 sec, iv) synthesis at 72�C for 40 sec and v) final elongation at 72�C for 10 min. 
8 lil of the 287 bp PGR product was digested with 5U Neil (New England BioLabs) 
restriction enzyme overnight at 60�C. The restriction digest products were resolved on 
a 2.5% agarose gel stained with ethidium bromide. The fragment lengths of the G 
allele were 263bp and 24bp,while the fragment length of the PGR product remained 
as 287bp when the A allele was present. Heterozygotes AG were indicated by the 
presence of the 24bp, 263bp and 287bp bands (see Fig. 18). 
2.4 DNA Sequencing 
DNA sequencing was employed to ensure the accuracy of the genotypes obtained. 
The PGR Clean Up-M system (Viogene, Catalog no. PFlOOl, USA) was used. Firstly, 
th6 PGR product was pipetted to a 1.5ml tube and lOO i^l of ddHzO was added. Then 
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0.5ml of buffer PX was added to the sample. After mixing well, the mixture was 
transferred to the PGR Clean Up-M column in a 2ml collection tube and then 
centrifuged for 1 min. After centrifugation, the filtrate was discarded and the column 
was washed and centrifuged for 1 min twice with 0.5ml wash I buffer and 0.7ml wash 
II buffer respectively. The column was further centrifuged for an additional 3 min in 
order to remove the ethanol residue. Finally, the column was placed into a new 1.5ml 
tube and then 30|il of ddHbO was added to the centre of the column. The tube was left 
to stand at room temperature for 1 min and DNA was eluted by centrifugation for 2 
min. 5^1 of purified PGR product was mixed with Ipd 3pmol/|il forward primer and 
4叫 of DNA Sequencing Kit dRhodamine Terminator Cycle Sequencing Ready 
Reaction (Perkin Elmer Biosystems, England). The sequencing reaction was carried 
out at 96°C for 10 sec, then 25 cycles for 96°C for 10 sec, 5 0 � C for 5 sec, 6 0 � C for 4 
min and finally 4°C for 7 min. Prior to DNA sequencing, an AutoSeq ™ G-50 column 
(Amersham Pharmacia Biotech Inc, USA) was used to remove the excess 
dRhodamine Terminator from the completed DNA sequencing reaction. DNA 
sequencing was then performed in an automated ABI Prism 310 Genetic Analyzer 
(Perkin Elmer Applied Biosystems, USA). 
2.5 Statistical Analysis 
2-tailed Yates chi square (x^) analysis was applied to compare the difference in allele 
and genotype frequencies between the heroin-dependent subjects and the controls. P < 
0.05 was considered statistically significant. To examine the interaction between 
genotypes, Yates test was also used to compare the frequencies of the combined 
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genotypes among control and heroin dependent subjects. 
Logistic regression is a variation of ordinary regression, useful when the observed 
outcome is restricted to two values, which usually represent the occurrence or non-
occurrence of some outcome event, (usually coded as 1 or 0，respectively). It produces 
a formula that predicts the probability of the occurrence as a function of the 
independent variables. In this study, logistics regression analysis was carried out by 
using SPSS to calculate the relative odds (RO) in determining the effects of the 
combined genotypes to see whether the difference in the dosage of variant genes that 
are carried by individuals will make the vulnerability to heroin dependence more 
robust or not (Noble et al” 1998). For instance, subjects who had the AA of A118G 
and CC of C1031G were scored as 0，this mean they had a zero dose of the 
susceptibility gene. Subjects who had the AA, AG of A l l 8 G or the CC, CG of 
C1031G were labeled as 1, this means they had a single dose of the susceptibility 
gene，while subjects who carried the AG, GG of A118G and CG, GG of C1031G 
were scored as 2, indicating that they had a double dose of the susceptibility gene. 
To explore the correlation between the genotypes and the factors in ASI, a { t e s t was 
also used. The heroin dependent subjects were divided into 2 groups: a less or a more 
severe group in 6 areas of ASI. Subjects who scored between 0-4 or between 5-9 were 
classified into the less or more severe group respectively. In addition, the correlation 
between factors in ASI was investigated by using x2 test and Pearson correlation 
coefficient (r). � 
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CHAPTER THREE RESULTS 
3.1 Socio-demographic Data 
3.1.1 Age of the Control and Heroin-dependent Subjects 
The age of the control and heroin-dependent subjects ranged from 18 to 57 and 16 to 
61 years respectively. The mean ages of the control and heroin-dependent subjects 
were 32.8±11.2 and 35.8±11.6 years respectively. When the age distribution was 
examined, it was found that 6 (6.2%), 42 (43.3%), 25 (25.8%), 15 (15.5%) and 9 
(9.3%) of the control subjects aged 11-20，21-30，31-40，41-50 and 51-60 years 
respectively (Fig. la). The age distribution of the heroin-dependent subjects was 28 
(14%)，39 (19.5%), 54 (27%), 63 (31.5%)，14 (7%) and 2 (1%) of them aged 11-20’ 
21-30，31-40, 41-50，51-60 and 61-70 respectively (Fig. lb). 
3.1.2 Educational Standard of the Heroin-dependent Subjects 
The educational standards of the heroin-dependent subjects ranged from 0 to 19 years 
with a mean of 9 .8±3.2 years. Amongst these subjects, 7 (3.5%) completed 0-3 years 
of education, 67 (33.5%), 119 (59.5%) and 7 (3.5%) subjects completed 4-9 (primary 
school)，10-13 (Form 1-3 of secondary school) and 14-19 (Form 4 to second year of 
University) years of education respectively (Fig. 2). Thus, 96.5% of subjects received 
a maximum education of up to Form 3 secondary school standard only. 
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Fig. la) Age distribution of control subjects (n=97). 







Age of Control Subjects 
I : 
d 
11-20 21-30 31-40 41-50 51-60 
Age 
b) 
Age of Heroin-dependent Subjects 
I II 
I 4 ^ ^ g j g l ^ H ^ ^ ^ M 
^ I _ _ _ 讓 菌 ^ ^ 
11-20 21-30 31-40 41-50 51-60 61-70 
Age 
� 
1 . , - - . - -
Fig. 2 The distribution of the educational standards in the heroin-dependent 
subjects (n=200). 
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3.1.3 Years of Heroin Use 
The years of heroin use range from 0.5 to 35 years, with an average of 14±9.1years. 
Amongst these subjects, 47 (23.5%) subjects had abused heroin for less than 5 years, 
38 (19%), 26 (13%), 53 (26.5%), 12 (6%) and 17 (8.5%) subjects had abused heroin 
for 6-10，11-15, 16-20, 21-25, 26-30 years respectively. 7 (3.5%) subjects had abused 
heroin for over 30 years (Fig. 3). 
3.2 Addiction Severity Index (ASI) 
Using the ASI (see Section 2.1.1.2; Appendix 1)，heroin-dependent subjects in this 
study were interviewed in areas such as medical, employment, drug, legal, 
family/social relationships and psychiatry status and background. In each area, an 
index was given to rate the severity. 
3.2.1 ASI - Medical 
Fig. 4a shows that among the 200 heroin-dependent subjects interviewed, 151 
subjects (75.5%) scored 0 for the medical category of the ASI. 20 subjects (10%) 
scored 1’ the remaining 29 (14.5%) subjects scored between 2 and 8. No individual 
scored a 9. 
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Fig. 3 The distribution of the no. of years of heroin use in the heroin-dependent 
subjects (n=200). 
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Fig. 4a) Distribution of ASI - Medical of 200 heroin-dependent subjects. 
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3.2.2 ASI - Employment 
Fig. 4b showed the ASI distribution of employment of the 200 heroin-dependent 
subjects to be within 4 to 8. 36 (18%) subjects scored a 4，while 52 subjects (26%) 
each scored 5 and 6 on the scale. 45 (22.5%) and 11 (5.5%) subjects scored 7 and 8 
respectively with the remaining 4 (2%) subjects distributed between 0 to 3 and 9. 
3.2.3 ASI - Drug 
Fig. 4c shows that the heroin-dependent subjects were distributed across the scale of 0 
to 9. 43 (21.5%) subjects scored 5’ 25 (12.5%), 28 (14%), 37 (18.5%) and 24 (12%) 
subjects scored 2，3，4 and 6 respectively. The remaining 43 (21.5%) subjects were 
distributed at index 0 - 1 and 7 - 9. Taken together, a total of 78.5% of subjects scored 
between 2 and 6 for drug. 
3.2.4 ASI-Legal 
Fig. 4d shows that 53 (26.5%) of heroin-dependent subjects had an index of 0‘ 23 
(11.5%)，35 (17.5%) and 22 (11%) subjects scored 1’ 2 and 3 respectively. 31 (15.5%) 
individuals scored between 4 to 6 and 36 (18%) subjects scored between 7 to 9. This 
indicated that more than half of the subjects had ASI from 0 - 3. 
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Fig. 4c) Distribution of ASI - Drug of 200 heroin-dependent subjects. 
4d) Distribution of ASI - Legal in heroin-dependent subjects. 
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3.2.5 ASI - Family/Social Relationships 
FigAe shows that the ASI scores of the heroin-dependent subjects were mostly found 
between 0 and 3. 74 (37%) subjects scored a 0, 30 (15%), 36 (18%) and 20 ' (10%) 
subjects scored aI, 2 and 3 respectively. The remaining 40 (20%) subjects scored in 
the indices ranges of 4 to 9. 
3.2.6 ASI - Psychiatry 
Fig. 4f shows that 86 (43%) subjects scored an index of O. 33 (16.50/0), 23 (11.5%) 
and 22 (11%) subjects scored 1,2 and 3 respectively. The remainding 36 (18%) 
scored between 4 and 7 with only 2 (1 %) of these subjects scoring 7. No subjects 
scored 8 or 9. Taken together, 82% of subjects scored between 0 and 3. 
3.2.7 Correlations Among the Factors of ASI 
Table 1 showed the correlations among the 6 ASI factors that were examined. 
Pearson's correlation showed statistically significant correlations between medical 
and family/social relationships status (p=0.004, r=0.192), medical and psychiatric 
status (p=0.002, r=0.244), employment and psychiatric status (p=O.OOO, r=0.274), 
drug and legal status (p=O.OOO, r=0.381) as well as family/social relationships and 
psychiatric status (p=O.OOO, r=0.465). 
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Fig. 4e) Distribution of ASI - Social relationships of 200 heroin-dependent subjects. 
4f) Distribution of ASI - Psychiatry of 200 heroin-dependent subjects. 
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Table 1 Correlation between the 6 ASI factors. Pearson correlation coefficients (r) 
are shown in the boxes. * indicates a statistical significance level at p<0.05. 
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Table 1 
Medical Employment I Drug Legal iFamily/Social I Psychiatry 
Relationships  
Medical 1 • 
Employment 0.111 1 
Drug 0.076 0.017 1 
Legal 0.001 0.072 *0.381 1 
Family/Social •0.192 0.181 - 0 . 0 1 9 i 
Relationships 
Psychiatry *0.244 *0.274 0 . 0 3 6 ^ O ^ ^ o ^ ；  
Pearson correlation coefficient (r) 
3.3 A118G Polymorphism in Exon 1 of the Human Mu Opioid Receptor 
(hMOR) Gene 
PCR products of exon 1 of the hMOR gene containing the A118G polymorphism 
were analyzed by dHPLC. The chromatogram of a heterozygous AG individual shows 
the presence of two well-resolved peaks (heteroduplex) (Fig. 5a). This was confirmed 
by direct sequencing (Fig. 5b). The polymorphic site is indicated by an arrow. An 
individual with homozygous AA or GG is characterized by the presence of a single 
peak in the chromatogram as observed in Figs. 6 and 7 respectively. In order to 
distinguish whether the single peak represents a homozygous AA or homozygous GG 
individual, each sample was mixed with a control DNA containing homozygous AA. 
If two well-resolved peaks (Fig. 8a) results from this mixture, the individual is 
homozygous GG due to the formation of a heteroduplex similar to that observed in 
heterozygous AG individuals. If a single peak results after the addition of the control 
DNA, the individual is a homozygous AA (Fig. 9a). Direct sequencing of the DNA 
gave a 100 % match to the results obtained from the dHPLC (Figs. 8b & 9b). The 
homozygous AA individual carried the sequence TGGCA while the homozygous GG 
individual carried the sequence TGGCG as indicated by the arrows (Fig.8b & 9b). A 
heterozygote individual carries both A and G. 
The distributions of genotype and allele frequencies of the A118G polymorphism of 
the hMOR gene in the control and heroin-dependent subjects are shown in Tables 2a 
V 
and 2b respectively. Table 2a showed that, out of the 97 control subjects, 51 (52.6%) 
of them carried the AA homozygous genotype, 11 (11.3%) carried the GG 
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Fig. 5a) Chromatogram of the A118G polymorphism of a heterozygous AG 
individual. Two well-resolved peaks are shown (indicated by arrow). 
b) The pattern of direct sequencing for the A118G polymorphism of a heterozygous 
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Fig. 6 Chromatogram of the A118G polymorphism of a homozygous AA individual. 
A single peak is shown (indicated by arrow). 
Fig. 7 Chromatogram of the A118G polymorphism of a homozygous GG individual. 
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Fig. 8a) Chromatogram of the A118G polymorphism of a homozygous GG 
individual. Two well-resolved peaks are shown (indicated by arrow) when control 
DNA (homozygous AA) was mixed with this sample. 
b) The pattern of direct sequencing for the A118G polymorphism of the 
homozygous GG individual. The arrow indicates the polymorphic site. 
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Fig. 9a) Chromatogram of the A118G polymorphism of a homozygous AA 
individual. A single peak (indicated by arrow) was observed after mixing the 
sample with control DNA (homozygous AA). 
b) Direct sequencing pattern for the A118G polymorphism of a homozygous 
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Table 2a) Distribution of genotype frequency of the A118G polymorphism of the 
hMOR gene in control and heroin-dependent subjects. The absolute number of cases 
and the percentage of total (in brackets) are shown. Yates analysis showed that 
% =6.176; df=2; p=0.046 for the comparison of heroin-dependent subjects and 
controls. 
b) Allelic frequencies of A and G of the A118G polymorphism of the hMOR gene 
in controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates f analysis showed that x^=5.792; 
df=l; p=0.016 for comparison of heroin-dependent subjects and controls. 
Table 2a 
Genotype  
AA AG I GG Total 
— Controls 51 (52.6%) 35 ( 3 6 . 1 ^ 11(11.3%) 97 _ 
Heroin -dependent subjects 75 07.5%) 92 (46.0%) 33 (16.5%) 
2b) 
Allelic frequency 
A G Total 
Controls 137 (70.6%)' 57 (29.4%) 194 
Heroin-dependent subjects 242 (60.5%) 158 ( 3 9 . 5 % ) 4 0 0 
homozygous genotype and 35 (36.1%) carried the heterozygous AG genotype. In 
comparison, of the 200 heroin-dependent subjects examined, 75 (37.5%) and 33 
(16.5%) of the subjects had homozygous genotype AA and GG respectively. 92 (46%) 
of the heroin-dependent subjects were AG heterozygous carriers. Yates ^ analysis 
between the control and heroin-dependent subjects showed a significant difference 
(X (2)=6.176; P=0.046) between the two groups. 
When the allelic frequencies was examined, allele G was observed in a larger 
proportion of heroin-dependent subjects than in the controls (39.5% vs. 29.4%; Table 
2b). The ^ test yielded a significant difference (5c2(i尸5.792; p=0.016) between the 
two groups. The higher proportion of G was shown to be due to an increase in the 
number of GG homozygotes (16.5% in the heroin-dependent subjects vs. 11.3% in the 
control population.). This difference was shown earlier to be statistically significant 
(p=0.046; Table 2a). Notably, the proportion of heterozygotes among the heroin-
dependent subjects was higher than that in the control population. Moreover the 
increase in GG homozygotes was accompanied by a decrease in AA homozygotes, 
this means the GG genotype is more common than the AA genotype in heroin-
dependent subjects than in controls. Furthermore, it was noted that the prevalence of 
the A allele was higher in the control group than in the heroin-dependent group 
(70.6% vs. 60.5%, see Table 2b). 
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3.4 C1031G Polymorphism in Intron 2 of the hMOR Gene 
The PGR product of 145bp size was subjected to Hinfl digestion and the resulting 
fragments were resolved on a 4% agarose gel that was stained with ethidium bromide. 
Genotype CC was represented by the presence of a single 124 bp band, whereas the 
genotype GG was represented by the presence of a 145 bp band. Both 124 bp and 145 
bp bands can be found in the heterozygote CG individual (Fig. 10). The results of 
genotyping were confirmed by direct sequencing (Figs, lla-c). A homozygous CC 
individual carries the sequence TAAAAATC while a homozygous GG individual 
carries sequence TAAAAATG as indicated by the arrows. A heterozygote individual 
carries both C and G. 
Tables 3a and 3b show the C1031G polymorphism in intron 2 of the hMOR gene. 
Table 3a reveals that 64 of the controls (66%) carried the CC homozygous genotype, 
8 controls (8.2%) carried the GG homozygous genotype and 25 (25.8%) were carriers 
of the CG genotype. In contrast, it was found that there were 108 (54%) and 31 
(15.5%) heroin-dependent subjects with CC and GG homozygous genotype 
respectively. 61 heroin-dependent subjects (30.5%) were CG heterozygous carriers 
(Table 3a). Yates analysis showed that =4.739; p=0.094. (NS) 
Table 3b shows the allelic frequencies of C and G alleles. The C allele was the most 
common allele in both controls (78.9%) and heroin-dependent subjects (69.3%). 
� 
However, the frequency of the G allele was found to be significantly higher 
(X^(1)=4.407; P=0.014) in the heroin-dependent subjects (30.8%) than in the controls 
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Fig. 10 A 145bp PCR product of the C1031G polymorphism of the hMOR gene was 
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Fig. 11a) The pattern of direct sequencing the CI031G polymorphism of the hMOR 
gene of a homozygous CC individual. The arrow indicates the polymorphic site. 
b) The pattern of direct sequencing the C1031G polymorphism of the hMOR gene of 
a heterozygous CG individual. The arrow indicates the polymorphic site. 
c) The pattern of direct sequencing the C1031G polymorphism of the hMOR gene of 
a homozygous GG individual. The arrow indicates the polymorphic site. 
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Table 3a) Genotype frequencies of the CI031G polymorphism of the hMOR gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates ^ analysis showed that x^=4.739; 
df=2; p=0.094 when heroin-dependent subjects were compared to the controls. 
b) Allelic frequencies of C and G of the CI031G polymorphism of the hMOR gene 
in controls and heroin dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates ^ analysis showed that 
df=l; p=0.014 when heroin-dependent subjects were compared to the controls. 
Table 3a) 
Genotype  
CC CG I GG Total 
— Controls "^ (66 .0%) 11(25.8%) 8 (8.3%) 97 —  
Heroin-dependent subjects! 108 (54.0%)| 61 (30.5%) 31 (15.5%) 200 
b) 
Allelic frequency  
C G Total 
— Controls T s s (78.9%) l l (21.1%) — 194 
Heroin-dependent subjects! 277 (69.3%) 123 ( 3 0 . 7 % ) ~ 
� 
(21.1%). It can be seen that the higher frequency of the G allele contributed to a two-
fold increase in the number of homozygous GG (15.5%) among the heroin-dependent 
subjects as compared with the controls (8.3%) (Table 3a). Furthermore, the high G 
allele frequency also contributed to the higher percentage of heterozygous CG 
observed in the heroin-dependent subjects (Table 3a). There was a concomitant 
decrease in the number of homozygous CC individuals in the heroin-dependent group 
as the number of heterozygous CG and homozygous GG individuals increased. 
3.5 T921C Polymorphism in the Exon 3 of the Human Delta Opioid Receptor 
(hDOR) Gene 
The PGR product of 106bp size was subjected to BstEll digestion and the resulting 
fragments were resolved on a 4% agarose gel that was stained with ethidium bromide. 
The results of the genotyping were confirmed by direct sequencing (Figs. 13a-c). A 
homozygous TT individual carries the sequence TGGGTT while a homozygous GG 
individual carries the sequence TGGGCT as indicated by the arrows. A heterozygote 
carries both T and C. 
Table 4 shows the T921C polymorphism in the exon 3 of the hDOR gene. Table 4a 
reveals that 59 controls (60.8%) carried the TT homozygous genotype, 4 controls 
(4.1%) carried the CC homozygous genotype and 34 (35.1%) were carriers of the TC 
heterozygote genotype. In the heroin-dependent group, it was found that there were 90 
(45%) and 11 subjects (5.5%) with TT and CC homozygous genotype respectively. 99 
59 
Fig. 12 A 106bp PCR product of the T921C polymorphism of the hDOR gene was cut 
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Fig. 13a) The pattern of direct sequencing the T921C polymorphism of the hDOR 
gene of a homozygous TT individual. The arrow indicates the polymorphic site. 
b) The pattern of direct sequencing the T921C polymorphism of the hDOR gene of a 
heterozygous TC individual. The arrow indicates the polymorphic site. 
c) The pattern of direct sequencing the T921C polymorphism of the hDOR gene of a 
homozygous CC individual. The arrow indicates the polymorphic site. 
Fig. 13a) 
C A C T G T G C A T C G C G C T G G G T T A C C C A A T A G C A 
40 50 n n A 60 7( 
1 aa a A I 
言 
b) 
ACC T GNTG C A T C G C G C T G G G T T ACCC C A A T A G C 




T G T G C A T C G C G C T G G G C T A C C C C A A T A G C A G C C T C A . 
50 60 70 
t 
Table 4a) Distribution of genotype frequency of the T921C polymorphism of the 
hDOR gene in controls and heroin-dependent subjects. The absolute number of cases 
and the percentage of total (in brackets) are shown. Yates x^ analysis showed that 
X =6.797; df=2; p=0.038 for comparison of heroin-dependent subjects and controls. 
b) Allelic frequencies of T and C of the T921C polymorphism of the hDOR gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates y^ analysis showed that x^=4.853; 
df=l; p=0.028 for comparison of heroin-dependent subjects and controls. 
Table 4a) 
Genotype  
TT TC CC Total 
Controls 59 (60.8%) "34 (35.1%) ~ 4 (4.1%) 97 
Heroin-dependent subjects! 90 (45.0%) 99 (49.5%) 11 (5.5%) ^ ~ 
b) 
Allelic frequency 
T C Total 
Controls 152 (78.4%)" 42 (21.6%)" 194 
Heroin-dependent subjects 279 (69.8%) 121 ( 3 0 . 3 % ) ^ 
V 
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heroin-dependent subjects (49.5%) were TC heterozygous (Table 4a). Yates ^ 
analysis showed that %2(2尸6.797; p=0.038. 
Table 4b shows the allelic frequencies of the T and C alleles. The T allele was the 
most common allele in both controls (78.4%) and heroin-dependent subjects (69.8%). 
The prevalence of the T allele in the control group was significantly higher 
(X � = 4 . 8 5 3 ; p=0.028.) than that of the heroin-dependent group, whilst a higher 
prevalence of the C allele was found in the heroin-dependent group (30.3%) than in 
the control group (21.6%). It can be noted that the higher frequency of the T allele in 
the control group contributed to the major genotype, homozygous TT (60.8%) and 
heterozygous TC group (35.1%). The number of homozygote TT individuals was 
almost doubled that of TC heterozygotes (59 vs. 34; Table 4a). The relatively high 
percentage of heterozygous TC subjects in the heroin-dependent group contributed to 
the high C allele frequency (49.5% vs. 35.1%，Table 4a). In the heroin-dependent 
group there was a decrease in the number of homozygous TT individuals as the 
number of heterozygous TC and homozygous CC individuals increased. 
3.6 Interaction Between Genotypes 
3.6.1 Combined Genotypes of A118G and C1031G Polymorphisms of hMOR 
Gene 
� 
Fig 14 shows the genotype distribution of the combined A118G and C1031G 
polymorphisms of the hMOR gene in the control and heroin-dependent subjects. 
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Fig. 14 Combined genotypes of the A118G and the CI031G polymorphisms of the 
hMOR gene in control and heroin-dependent subjects. Subjects who had the AA of 
A118G and CC of C1031G were scored as 0，this means they had a zero dose of the 
susceptibility gene. Subjects who had the AA, AG of A118G or the CC, CG of 
C1031G were labeled as 1，this means they had a single dose of the susceptibility 
gene. Subjects who carried the AG, GG of A118G and CG, GG of C1031G were 
scored as 2’ this indicates that they had a double dose of the susceptibility gene. 
• � - - . 
Fig. 14a) Distribution of combined genotypes of the A118G and the C1031G 
polymorphisms of the hMOR gene in controls and heroin-dependent subjects. 
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Individuals who carried the 0, 1 or 2 genotype corresponded to those who had zero, 
single or double dose of the susceptibility genotypes. Subjects with the 1 vs 0, 1 vs 2 
and 2 vs 0 genotypes were compared. % tests showed statistical significance in 1 vs 0 
and 2 vs 0 genotypes. However, the highest relative odds (RO) were found when the 2 
vs 0 genotypes were compared between controls and heroin- dependent subjects 
(RO=3.396, p=0.001; see Table 5a). 
3.6.2 Combined Genotypes of A118G Polymorphism of the hMOR Gene 
and the T921C Polymorphism of the hDOR Gene 
Fig 15 shows the genotype distribution of the combined A118G polymorphism of the 
hMOR gene and the T921C polymorphism of the hDOR gene in controls and heroin-
dependent subjects. Individuals who carried 0，1 and 2 genotypes correspond to those 
who had zero, single and double dose of susceptibility genotypes. Subjects with the 1 
vs 0，1 vs 2 and 2 vs 0 susceptibility genotypes were compared, x tests showed 
statistical significance in the 1 vs 2 and 2 vs 0 genotypes. The highest relative odds 
(RO) were found when the 2 vs 0 genotypes were compared between controls and 
heroin-dependent subjects (RO=3.434, p=0.0005; see Table 5b). 
3.6.3 Combined Genotypes of the C1031G Polymorphism of the hMOR Gene 
and the T921C Polymorphism of the hDOR Gene 
N 
Fig 16 shows the genotype distribution of the combined C1031G polymorphism of 
the hMOR gene and the T921C polymorphism of the hDOR gene in controls and 
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Table 5 Relative Odds (RO) determined by logistic regression analysis of the 
combined effects of A118G, C1031G and T921C genotypes. Yates Chi-square test 
was used to compare the prevalence of these combined genotypes between the 
controls and heroin-dependent subjects. * Indicates statistical significance level at 
p<0.05. 
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Table 5 
Relative Odds ^ value P-value 
A. Combined A118G and C1031G 
1 vs 0 genotypes 2.026 5.738 *0.017 
1 vs 2 genotypes 1.676 2.268 0.132 
2 vs 0 genotypes 3.396 10.358 *0.001 
B. Combined A118G and T921C 
1 vs 0 genotypes 1.476 1.665 0.197 
1 vs 2 genotypes 2.327 7.073 *0.008 
2 vs 0 genotypes 3.434 11.970 *0.001 
C. Combined C1031G and T921C 
1 vs 0 genotypes 1.967 5.824 *0.016 
1 vs 2 genotypes 1.790 2.419 0.120 
2 vs 0 genotypes 3.520 10.211 *0.001 
Fig. 15 Combined genotype of the A118G polymorphism of the hMOR gene and the 
T921C polymorphism of the hDOR gene in control subjects and heroin-dependent 
subjects. Subjects who had the AA of A118G and TT of T921C were scored as 0, this 
means they had a zero dose of susceptibility gene. Subjects who had the AA, AG of 
A118G or the TC, TT of T921C were labeled as 1，this means they had a single dose 
of susceptibility gene. Subjects who carried the AG, GG of A118G and TC, CC of 
T921C were scored as 2, this indicates that they had a double dose of susceptibility 
gene. 
Fig. 15a) Distribution of combined genotypes of the A118G polymorphism of the 
hMOR gene and the T921C polymorphism of the hDOR gene in controls and heroin-
dependent subjects. 
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Fig. 16 Combined genotype of the C1031G polymorphism of the hMOR gene and 
the T921C polymorphism of the hDOR gene in control and heroin-dependent 
subjects. Subjects who had the CC of C1031G and TT of T921C were scored as 0， 
this means they had a zero dose of susceptibility gene. Subjects who had the CC, CG 
of C1031G or the TC, TT of T921C were labeled as 1，this means they had a single 
dose of susceptibility gene. Subjects who carried the CG, GG of C1031G and TC, CC 
of T921C were scored as 2, this indicates that they had a double dose of susceptibility 
gene. 
Fig. 16a) Distribution of combined genotypes of the CI 031G polymorphism of the 
hMOR gene and the T921C polymorphism of the hDOR gene in controls and heroin-
dependent subjects. 
Groups Genotype 
： 0 1 2 
Controls (n=97) ^ 49 U 
Heroin-dependent 43 112 45 
subjects (n=200) 
b) Bar-chart representation of a) 
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of the hMOR gene and the T 92IC polymorphism 
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heroin-dependent subjects. Individuals who carried 0，1 and 2 genotypes corresponded 
to those who had zero, single and double dose of susceptibility genotypes. Subjects 
with the 1 vs 0，1 vs 2 and 2 vs 0 susceptibility genotypes were compared. % tests 
showed statistical significance in 1 vs 0 and 2 vs 0 genotypes. The highest relative 
odds (RO) were found when the 2 vs 0 genotypes were compared between controls 
and heroin addicts (R0=3.520, p=0.001; see Table 5c). 
3.7 Correlation Between Allelic Frequencies and Factors of the ASI 
Table 6 shows the correlation between allelic frequencies and the different factors 
such as medical, employment, drug, legal, family/social relationships and psychiatry 
of the ASI.义2 tests showed statistically significant correlations between allelic 
frequencies and ASI factors between the G allele of the CI031G polymorphism and 
family/social relationships status (p=0.00005) as well as psychiatric status 
(p=0.0068). 
3.8 3，VNTR Polymorphism of the DAT Gene 
From Table 7a, it can be observed that the 10-repeat allele occurs most frequently in 
the Hong Kong population. The next most common one is the 9-repeat allele. The 9-
repeat allele can be revealed by the presence of a 440bp band. The 6, 7, 10 and 11-
repeat allele were indicated by the presence of 320bp, 360 bp, 480bp and 520bp bands 
respectively (Fig 17). The genotype frequencies of 3，VNTR of the DAT gene were: 1 
with genotype 6/6，2 with 9/9，5 with each of 10/7and 11/10，33 with 10/9，198 with 
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Table 6 Correlation between allelic frequencies and factors of ASI. Subjects scored 




A118G of hMOR (allele A vs allele G) 
less severe subjects compared to more severe subjects  
Medical 0.195 1 
Employment 0.666 1 
Drug 0.295 1 
Legal 0.887 1 
Family/Social relationships 0.755 1 
Psychiatry 0.078 1 
C1031G of hMOR (allele C vs allele G) 
less severe subjects compared to more severe subjects  
Medical 0.639 1 
Employment 0.180 1 
Drug 0.067 1 
Legal 0.057 1 
Family/Social relationships *0.00005 1 
Psychiatry “ *0.0068 1 
T921C of hDOR (allele T vs allele C) 
less severe subjects compared to more severe subjects  
Medical 0.744 1 
Employment ~~ 0.818 1 
Drug 0.266 T " 
Legal 0.533 1 
Family/Social relationships 0.757 1 
Psychiatry 0.616 1 
3，VNTR of DAT (allele 9 vs allele other than 9) 
less severe subjects compared to more severe subjects  
Medical 0.133 1 
Employment 0.143 1 
Drug 0.299 1 
Legal � 0.397 1 
Family/Social relationships 0.174 1 
Psychiatry 0.829 1 
TaqlA polymorphism of DRD2 (allele Al vs allele A2) P-value df 
less severe subjects compared to more severe subjects  
Medical 0.422 1 
Employment 0.319 1 
Drug 0.175 1 
Legal 0.276 1 ^ 
Family/Social relationships 0.275 1 
Psychiatry 0.283 1 
Neil polymorphism of GABRG2 (allele A vs allele G) 
less severe subjects compared to more severe subjects  
Medical 0.675 1 
Employment “ 0.576 1 
Drug • 0 .425~~ 1 
Legal 0.639 1 
Family/Social relationships 0.176 1 
Psychiatry 0.236 1~~ 
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Table 7a) Genotype frequencies of the 3，VNTR polymorphism of the DAT gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. 
b) Genotype frequencies of allele 9 of the 3，VNTR of the DAT gene in controls and 
heroin-dependent subjects. The absolute number of cases and the percentage of total 
(in brackets) are shown. Yates y^ analysis showed that %^=1.311; df=2; p=0.519 when 
heroin-dependent subjects were compared to the controls. * indicates an allele other 
than 9 of the DAT gene. 
c) Allelic frequencies of the 9 allele and an allele other than 9 of the 3，VNTR of the 
DAT gene in controls and heroin-dependent subjects. The absolute number of cases 
and the percentage of total (in brackets) are shown. Yates ^ analysis showed that 
% =0.871; df=l; p=0.351 when heroin-dependent subjects were compared with the 
controls. * indicates an allele other than 9 of the DAT gene. 
Table 7a) 
— Genotype 
6/6 9/9 10/7 10/9 10/10 11/10 " T ^ 
Controls 0(0%) 0(0%) 2 (2.4%) "lO (12%) "^(81 .9%) 
Heroin-dependent subjects|l (0.6%)12 (1.2%)13 (1.9%)123 (14.3%)| 130 (80.7%)|2 a .2%)| 161 
b) 
Genotype  
9/9 9/‘ I */* Total 
Controls 0(0%) — 10(12%) “ 73 (88%) 
Ifaoin-dependent subjects! 2 (1.2%) 23 (14.3%) 136 (84.5% 161 
c) 
Allelic frequency (number of repeat) 
9 I * Total 
Controls 10 (6%) “ 156 (94%) 166 — 
Heroin-dependent subjects 27 (8.4%) 一 295 (91.6%) 3 2 2 “ 
r- 、 
-
Fig. 17 Observed alleles ranged from 6 to 11 repeats (320-520bp). The 6/6, 9/9’ 
10/10 genotypes can be seen by the presence of the band with size 320bp, 440bp and 
480bp respectively. 10/7，10/9 and 10/11 genotypes can be identified by the band size 
480bp and 360bp; 480bp and 440bp; 480bp and 520bp respectively. 
Fig. 17 
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10/10. Collapsing the genotypes according to the presence of the 9-repeat allele (9/9 
or 9/*) or absence of it (*/*)，it may be seen (Table 7b) that, none of the controls (0%) 
carried the 9/9 homozygous genotype and 73 controls (88%) carried the */* 
homozygous genotype. The rest of them (12%) were carriers of the 9/* heterozygous 
genotype. In contrast, it was found that there were only 2 heroin-dependent subjects 
(1.2%) and 136 heroin-dependent subjects (84.5%) with 9/9 homozygous and */* 
homozygous genotype respectively. 23 heroin-dependent subjects (14.3%) were 9/* 
heterozygous carriers (see Table 7b). 
From Table 7c, it was found that the percentage of carriers of the 9-repeat allele was 
not significantly different between the control and the heroin-dependent group (6% vs 
5.4%). So was the distribution of a carrier with allele other than 9 in both groups 
(94% vs 91.6%). Therefore, the present study revealed no statistically significant 
difference between heroin-dependent subjects and controls in both genotype 
(p=0.519) and allelic frequencies (p=0.351) as shown in Table 6b and 6c. 
3.9 Taql A Polymorphism of the DRD2 Gene 
From Table 8a, it may be seen that 11 controls (12.4%) carried the Al homozygous 
genotype and 27 controls (30.3%) carried the A2 homozygous genotype. The 
remainder (57.3%) were carriers of the A1A2 genotype. In comparison, it was found 
that there were 28 (16.1%) and 56 (32.2%) heroin-dependent subjects having Al 
homozygous and A2 homozygous genotypes respectively. 81 heroin-dependent 
subjects (51.7%) were A1A2 heterozygous carriers (see Table 8a). 
6 3 
Table 8a) Genotype frequencies of the Taql A polymorphism of the DRD2 gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates H� analysis showed x^=0.959; df=2; 
p=0.619 when heroin-dependent subjects were compared with the controls. 
b) Allelic frequencies of Al and A2 of Taql A polymorphism of the DRD2 gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates analysis showed %^=0.043; df=l; 
p=0.836 when heroin-dependent subjects were compared with the controls. 
Table 8a) 
Genotype  
A lAl A1A2 A2A2 Total 
Controls " l l (12.4%) l l (57.3%) ~TI (30.3%) 8 9 — 
Heroin-dependent subjects! 28 (16.1%) 90 (51.7%)" 56 (32.2%) ~ m 
b) 
Allelic frequency 
Al A2 Total 
Controls “ 73 (41.0%) 105 (59.0%) 178 
Heroin-dependent subjects! 146 ( 4 2 . 0 ^ 202 (58.0%) 348 
From Table 8b, it may be seen that the A2 allele was the most common allele in both 
controls (59%) and heroin-dependent subjects (58%). Moreover, a slightly higher 
prevalence of the A2 allele was found in the control group (59% vs 58%) as compared 
with the heroin-dependent group. It was proposed that the Al allele maybe the 
potential allele for the contribution in predisposition of heroin dependence. However, 
there was no significant difference between the frequencies of Al allele in the control 
(41%) and heroin-dependent group (42%)(p=0.836; Table 8b). It can also be observed 
that there was no statistically significant difference between heroin-dependent 
subjects and controls in the genotype frequency (p=0.619) as shown in Table 8a for 
the Taql A polymorphism of the DRD2 gene. 
3.10 Neil Polymorphism of the GABRG2 Gene 
The 287bp PCR product was subjected to Neil digestion and the resulting fragments 
were resolved on a 5% agarose gel that was stained with ethidium bromide. Genotype 
AA was revealed by the presence of a single 287 bp band, whereas genotype GG was 
represented by the presence of a 263 bp band and the absence of 287 bp band. Both 
the 287 bp and 263 bp bands were found in the heterozygote AG sample (Fig. 18). 
Table 9a shows that 1 control (1%) carried the AA homozygous genotype and 49 
controls (51%) carried the GG homozygous genotype. The rest of the group (47.9%) 
carried the AG genotype. It was found that there were 12 heroin-dependent subjects 
(7.1%) and 97 heroin-dependent subjects (57.1%) with AA homozygous and GG 
homozygous genotype respectively. 71 heroin-dependent subjects (41.8%) were AG 
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Fig. 18 The 287 bp PCR product was subjected to Neil digestion and the resulting 
fragments were resolved on a 5% agarose gel that was stained with ethidium bromide. 
A DNA marker (1 kb DNA ladder) was loaded on the left. 
Fig. 18 
DNA marker 
Table 9a) Genotype frequencies of the Neil polymorphism of the GABRG2 gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates analysis showed %^=5.073; df=2; 
p=0.079 when heroin-dependent subjects were compared with the controls. 
b) Allelic frequencies of A and G of the Neil polymorphism of the GABRG2 gene in 
controls and heroin-dependent subjects. The absolute number of cases and the 
percentage of total (in brackets) are shown. Yates analysis showed x^=0.540; df=l; 
p二0.462 when heroin-dependent subjects were compared with the controls. 
Table 9a) 
Genotype  
AA AG I GG Total 
- Controls —1(1.%) "46(47.9%) 49 (51%) 9 6 ~ 
Heroin-dependent subjects! 12 p .1%) 71 (41.8%) 87 (51.2%) 170 
b) 
Allelic frequency 
A I 6 Total 
“ Controls “ 48 (25%) " 144 (75%) “ 192 
Heroin-dependent subjects! 95 (27.9%)| 245 (72.1%| 340 
heterozygous carriers (see Table 9a). 
Table 9b shows that the G allele was the most common allele in both controls (75%) 
and heroin-dependent subjects (72.1%). Moreover, a slightly higher prevalence of the 
A allele was found in the heroin-dependent group (27.9% vs 25%) as compared with 
the control group. However, there was no significant difference in allele frequencies . 
between the control and heroin-dependent group (p=0.46; Table 9b). A statistically 
significant difference between heroin-dependent subjects and controls was also not 
observed in the genotype frequency (p=0.07) as shown in Table 9a for the Neil 
polymorphism of the GABRG2 gene. 
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CHAPTER FOUR DISCUSSION & CONCLUSION 
In the present study, the involvement of polymorphisms at the hMOR, hDOR, DAT, 
DRD2 and GABRG2 genes in heroin dependence were examined. Polymorphisms 
that were investigated included the A118G polymorphism at exon 1，the CI031G 
polymorphism at intron 2 of the hMOR gene, the T921C polymorphism at exon 3 of 
the hDOR gene, the 3' VNTR polymorphism of the DAT gene, the Taq\ A 
polymorphism of the DRD2 gene and the Neil polymorphism of the GABRG2 gene. 
Statistical significance was found between the heroin-dependent and control subjects 
of the A118G polymorphism of the hMOR gene in both the genotype (p=0.046; see 
Table 2a) and allelic frequencies (p=0.016; see Table 2b). A significant difference 
was also found in the allelic frequency (p=0.014; see Table 3b) of the C1031G 
polymorphism of the hMOR gene as well as the genotype (p=0.038; see Table 4a) and 
the allelic frequencies (p=0.028; see Table 4b) of the T921C polymorphism of the 
hDOR gene. However, no statistical significance was found in the polymorphisms of 
the DAT, DRD2 and GABRG2 genes (see Tables 7-9). 
Addiction Severity Index Data 
Apart from investigating into associations of the different gene polymorphisms 
between the heroin-dependent and control subjects, ASI was also obtained from the 
heroin-dependent subjects to study various profiles that are related to addiction 
behaviour. . � 
From the distribution of ASI - Medical status, it was shown that 151 (75.5%) subjects 
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scored a 0，meaning no medical problems exist and treatment is probably not 
necessary. Only 10% of the subjects scored a 1 and 14.5% of the subjects were 
distributed between 2-8 on the scale. Thus, the medical status of 85.5% of the heroin-
dependent subjects studied was satisfactory. Therefore medical problem may not be 
the major factor that contributes to heroin dependence because they did not suffer 
from serious illness which requires the use of heroin to relieve pain. This suggestion 
is consistent with the result of the correlation among ASI factors. No statistical 
significance was found between medical and drug factors. Significant correlation was 
only found between medical and family/social relationships status (p=0.004, r=0.192; 
Table 1). From the distribution of the education standards of the heroin-dependent 
subjects, it was found that 96.3% of these subjects have an education level of no more 
than Form 3 standard. As a result, the majority of them work irregular hours each 
week and their jobs are often part-time in nature. From the distribution of the ASI 一 
Employment indices, it can be seen that the majority of them were distributed at 4 to 8 
on the scale, suggesting a problem with obtaining employment. This is probably 
related to their educational background, which resulted in a lack of marketable skills, 
thus contributing to them having employment problems. Moreover, Pearson's 
correlation showed that a statistical significance was found between employment and 
psychiatry (p:=5.63xlO-5’ r二0.274; Table 1). This suggests that lack of employment 
may precipitate psychiatric symptoms like depression, anxiety, tension or even suicide 
attempts. 
The ASI 一 Drug distribution showed that the majority (78.5%) of the subjects was 
distributed between 2 to 6 on the scale with 21.5% of subjects scoring 0 - 1 and 7 - 9. 
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This suggests that the majority of them have a drug problem. Since all of these 
subjects were diagnosed to be heroin-dependent based on the DSM IV diagnostic 
criteria and that the average age of drug use is 14 ± 9.1 years (Fig. 3)，it is therefore 
not surprising that nearly 80% of subjects experienced drug-related problems. A 
significant correlation was found between drug and legal factor (p=4.91xl0-4’ 
r=0.381; Table 1). This maybe due to the frequent police charges that these subjects 
received for possession of drugs or drug paraphernalia. 
In the ASI - Family/social relationships section, the heroin-dependent subjects were 
asked about the nature of their relationships with their family members and friends. 
37% of subjects showed they had no problems (score of 0) in getting along with their 
family and friends. 43% of them scored between 1 and 3 and 20% of subjects scored 
between 4 - 9 on the scale. Significant correlations were found between family/social 
relationships and medical (p=0.004, r=0.192; Table 1) status as well as family/social 
relationships and psychiatry status (p=3.76xl0-7, r=0.465; Table 1). It is suggested 
that the medical and emotional problems experienced by the heroin-dependent 
subjects may result in poor inter-personal relationships, which may in turn result in 
conflicts with family members and friends. 
The distribution of ASI - Psychiatry showed that 82% of the subjects scored between 
0 to 3 on the scale. According to the ASI questions asked, the emotional problems 
they experienced like serious depression, anxiety, tension, problems in concentration 
and violent behaviour are mainly attributed to the dissatisfaction with employment, 
family/social relationships or the success in detoxification. Therefore, it is reasonable 
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to see there were significant correlations between psychiatry related problems and 
employment (p=5.63xl0-^ r=0.274; Table 1), family/social relationships (p=3.76xlO-
7，r=0.465, Table 1) and medical status (p=0.002, r=0.244; Table 1). 
Thus，3 (medical, employment and family/social relationships) out of 5 (medical, 
employment, drug, legal and family/social relationships) factors in the ASI were 
found to be correlated with psychiatric problems but not with drug problems. It seems 
therefore that environmental factors mainly affect the psychiatry status of the heroin-
dependent subjects and not directly the nature of heroin dependence. For the heroin-
dependent aspect, it has been suggested that genetic factor may play a major role in 
heroin dependence. It was been stated that in heroin abuse, a large unique contribution 
(38%) can be linked directly to be from genetic factors when compared to other drugs 
like marijuana, stimulant, sedative or psychedelic drugs (Tsuang et al., 1998). The 
present findings are in support of this tenet since ASI only showed a significant 
correlation between drug and legal status and not with other factors like psychiatry 
and medical. 
In order to examine whether there is a correlation between the genetic and 
environment factors, the correlation between factors of ASI and allelic frequencies 
was also studied. Statistically significant correlations were found only between the 
C1031G polymorphism of the hMOR gene and family/social relationships status 
(p=0.00005) as well as psychiatric status (p=0.0068). Although the functional role of 
� 
the C1031G polymorphism at intron 2 of hMOR gene is still unclear, it may be 
possible that this polymorphism or other nearby mutation site which is in linkage 
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disequilibrium with itself may play a role in the determination of personality or 
susceptibility to psychiatric disorders of these heroin-dependent subjects, which may 
in turn account for the poor relationships that they have with family members and in 
the society. 
A118G Polymorphism in Exon 1 of the hMOR Gene 
The biological aspect of heroin dependence has been investigated in recent years. It 
was hypothesized that reward is tonically activated by p-endorphin, an endogenous 
opioid that activates the MOR (Herz 1997). The functional significance of 
endogenous p-endorphin in reward also emerges from experimental results in rats 
with bilateral radiofrequency lesions of the mediobasal hypothalamus, whose 
hypothalamic |3-endorphin content was largely abolished. Results showed a marked 
reduction in their display of aversive effects to naloxone. The attenuated aversive 
effects of the opioid antagonist are explained in terms of reduced P-endorphin release 
in limbic areas (Khachaturian et al , 1985; Mucha et al., 1985; Herz 1997). 
The MOR is the primary action site for heroin and endogenous p-endorphin 
(Pasternak anf Wood 1986). The A118G variant of MOR binds P-endorphin 
approximately 3 times more tightly than the wild type MOR. Also, P-endorphin is 
approximately 3 times more potent at the A118G variant MOR when compared with 
the wild type receptor. These results indicated that the A118G polymorphism of MOR 
� 
can alter binding and signal transduction in the receptor and may have implications 
for normal physiology, therapeutics and vulnerability to develop diverse diseases 
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including heroin addiction (Bond et al, 1998). These authors showed a significant 
difference in allele frequency for exon 1 of Al l8G (p=0.028) amongst the Hispanics, 
Africa-Americans and Caucasians irrespective of their opioid dependence status. 
However, it was noted that within the Hispanics but not in Africa-Americans or 
Caucasians, the A118G variant allele was present in a significantly higher proportion 
ofnon-opioid-dependent subjects when compared with the opioid-dependent subjects. 
This suggests that ethnic variance exists for these mutations. In view of this finding, 
we have attempted to screen DNA samples from heroin-dependent as well as control 
Chinese subjects for the A118G exon 1 polymorphism in order to establish whether 
such ethnic variance also exists in the Chinese population. The results in the present 
study showed that a significant association also exists for the A118G polymorphism 
in the hMOR gene in the Chinese heroin-dependent subjects. The findings showed 
that the A allele is more common than the G allele in both control and heroin-
dependent subjects. However, more heroin-dependent subjects were shown to carry 
the G allele than the controls. The increase of G allele was due to the increase in GG 
and AG genotypes with a decrease in the number of AA genotype. With these 
findings，it could be concluded that the A118G polymorphism may be involve in 
heroin addiction. This study suggested that the A allele may have a protective role in 
the development of heroin dependence. With the increase in G allele and decrease in 
/ 
A allele in the heroin-dependent subjects, it may be concluded that subjects with the 
A118G variant of MOR, with 3-times higher affinity and potency for |3 -endorph in , 
may in turn make the individual more predisposed to heroin dependence. This 
� 
suggested that the genetic susceptibility to heroin dependence may be related to an 
increased responsiveness of the endogenous opioid system to heroin. Therefore, the 
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difference in sensitivity to the rewarding effect of heroin may account for the different 
extent of vulnerability to heroin dependence. 
On the contrary, Bond et al. (1998) suggested that the G allele might have a relative 
protective function in opioid dependence among the Hispanics since the A118G 
variant was present in a significantly (p=0.0041) higher proportion in the non-opioid-
dependent Hispanic subjects. When the allelic frequency of the Chinese population in 
the present study was compared to the three different ethnic groups reported in Bond 
et al. (1998)，the A allele frequency in both the control (70.6%) and heroin-dependent 
subjects (60.5%) in the Chinese subjects were lower to that reported in the Africa-
American (98.4%), Caucasian (88.5%) and Hispanic (85.8%) subjects (Bond C et al•， 
1998). This suggests that the Chinese population is more predisposed to heroin 
dependence as compared with another three populations (see Appendix III). These 
authors claimed that this may be due to the differences in allelic frequencies in 
different populations since a significant difference of allele frequencies exist among 
Africa-Americans, Caucasians and Hispanics irrespective of opioid dependence 
(p二0.028) (Bond et al., 1998). However, the difference in allelic frequency of 10.1% 
for the A118G variant in the present population is similar to that reported in other 
studies (Berrettini et a l , 1997; Bond et a l , 1998). Therefore, this maybe the result of 
a linkage disequilibrium in the different populations being reversed with the causative 
mutation being nearby. That means a causative mutation may have arisen 
independently in different populations (Breen et al., 1999). As a result, one is near the 
� 
A allele and another is near the G allele. Thus, G allele was found to be a predispose 
factor in the Chinese population while the A allele may be a risk factor in the Africa-
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American, Caucasian or Hispanic populations. 
In addition, the A118G variant predicts an Asn-to-Asp change in amino acid residue 
40 of the receptor. This residue in the most common sequence of the MOR is a 
putative site for N-glycosylation (Mestek et al., 1995). Thus, the A118G variant 
would result in the loss of a putative N-glycosylation site. The position of amino acid 
40 is in the N-terminal region of the MOR, which is predicted to be in the 
extracellular space (Chen et al, 1993). It remains to be determined whether there is 
any variant of the hMOR gene that can alter the tertiary structure of the MOR or 
change gene expression, which may account for the inter-individual differences in the 
predisposition to heroin dependence. 
C1031G Polymorphism in Intron 2 of the hMOR Gene 
A C1031G polymorphism in intron 2 of the hMOR gene was also investigated. It was 
chosen to see if other variants of the hMOR gene also confer a relevant effect on 
heroin dependence. A significant difference in allelic frequency was found between 
the heroin-dependent and control subjects. It seemed that the G allele might play a 
role in the predisposition of heroin dependence since there is a significant increase in 
allelic frequency for the G allele in the heroin-dependent subjects. However, no 
significant difference was found in the genotype frequency (p=0.094) although a trend 
can be observed, as it can be noted that the number of GG homozygotes in the heroin-
V 
dependent subjects was double that of the controls. The functional role of this 
polymorphism on heroin dependence, however, remains to be determined. Limited 
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studies revealed that morphine-6(3-glucuronide (M6G) and heroin did not produce 
antinociceptive responses in MOR knockout mice generated by the deletion of exons 
2 and 3 (Kitanaka et al , 1998; Loh et al , 1998) but retained antinociceptive activities 
in mice generated by an exon 1 deletion (Schuller et al., 1999). Significant levels of 
M6G binding and the presence of mRNAs detected with the exon 2 and 3 primers 
were demonstrated in mutant mice with a MOR exon 1 deletion. The observations 
suggest the exon 2 and 3 of the hMOR gene may be specific for the M6G 
pharmacological actions (Law et al , 2000). 
Binding studies demonstrated that humans differ from one another in their MOR 
densities in the brain (Uhl et al., 1999). Furthermore, MOR densities have been 
shown to be higher in alcohol-preferring rats relative to their non-preferring 
counterparts in the NAc and VTA (de Wade et al., 1995; Soini et al” 1999). It was 
postulated that a link may exist between MOR binding potential and alcohol 
preference (Roberts et al” 2000). Thus, it is worth noting that the possibilities of the 
involvement of polymorphisms in exons 1 and 2 of hMOR gene in the expression of 
MOR，which in turn may affect the susceptibility to heroin dependence. 
The combined genotypes of the A118G and the C1031G polymorphisms of the 
hMOR gene in the control and heroin-dependent subjects revealed that the 
vulnerability of heroin dependence is more robust when the individual carries a 
double dose (GG of A118G and GG of C1031G) of A118G and C1031G 
� 
polymorphisms than in those who carry a zero or single dosage (p=0.001, RO=3.396; 
see Table 5). This further supports an association of the G allele with susceptibility to 
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heroin dependence. In addition, it was proposed that the hMOR is likely a genetic risk 
factor associated with heroin dependence. 
T921C Polymorphism in Exon 3 of the hDOR Gene 
Several studies have proposed that the hDOR gene may be critical in the development 
of morphine-induced tolerance and dependence (Abdelhamid et al., 1991; Suzuki et 
al., 1994; Fundytus et al., 1995; Kest et al , 1996). The present study revealed a 
significant difference in allelic variation in exon 3 of the hDOR gene between the 
heroin-dependent subjects and the controls. The T allele was more frequent than the C 
allele in both the control group and heroin-dependent groups. A higher percentage of 
the heroin-dependent subjects carried the C allele, due to an increase in CC and TC 
genotypes with a decrease in TT. The correlation between the genotype of the T921C 
polymorphism of the hDOR gene and heroin dependence suggested a causal 
contribution of genetic variation in the hDOR gene to the development of heroin 
addiction, although the mechanism is still unclear. The presence of the C allele was 
previously suggested to significantly increase the risk for heroin dependence in a 
German population when the C17T polymorphism was examined (Mayer et al , 
1997). It can be suggested that CC homozygous carriers may be more predisposed to 
heroin dependence. On the other hand, TT homozygotes may play some sort of role in 
the prevention from addiction. This means that the C and T allele seems to favour and 
discourage heroin addiction respectively. 
The mechanisms underlying the association between T921C polymorphism of the 
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hDOR gene and heroin dependence remain unknown. Since the silent T to C 
transition in the coding region did not alter the receptor protein sequence (Mayer et 
al., 1997), the T921C polymorphism may not be the functional variation that 
contributes to heroin dependence. However, it has been demonstrated that there is an 
upregulation of the DOR binding site accompanying the development of morphine 
tolerance and dependence in mice (Abdelhamid and Takemori, 1990). Therefore, it 
was speculated that either the reported polymorphism in exon 3 itself or another 
closely linked polymorphism within the gene could alter the expression of the hDOR 
gene. Gelernter and colleagues identified one novel variant in exon 1, T80G 
polymorphism of the hDOR gene, which predicts a change in amino acid sequence 
from phenylalanine (SOT) to cysteine (80G) (Glernter and Kranzler, 2000). As a 
result, further experiments might reveal whether this variant would contribute to the 
previously reported association results involving a T921C polymorphism. In addition, 
a double dose (GG of A118G and CC of T921C) of A118G and T921C 
polymorphisms gives a robust susceptibility to heroin dependence (p=0.001, 
RO=3.434; Table 5). Furthermore, a more robust vulnerability to heroin dependence 
was found in subjects that carried a double dose (GG of C1031 and CC of T921C) of 
C1031G of hMOR and T921C of hDOR polymorphisms (p=0.001, R0=3.520; Table 
5). 
3，VNTR Polymorphism of DAT Gene 
Previous studies have shown an interaction between the opioid system in the brain 
with that of the dopamine system (Kalivas and Duffy, 1990; Acquas et al., 1991; 
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Leone et a l , 1991; Spanagel et al., 1992). Since opioids have the ability to increase 
dopamine release in the NAc, this action has been suggested to be related to their 
reinforcing properties (Van Ree et al” 1999). Moreover, animals will press a lever to 
receive injections of opioids directly into the VTA, wherein the cell bodies of the 
mesocorticolimbic dopaminergic system are located (Van Ree and De Wied, 1980; 
Bozarth and Wise, 1981b; Welzl et al., 1989) and such injection increase dopamine 
release in the NAc (Leone et al , 1991; Rada et a l , 1991). DAT is the key element in 
controlling dopamine levels at the synapse. In the present study, the possibility of the 
contribution of the dopamine receptor and transporter genes to the vulnerability of 
heroin dependence was also investigated. 
198 out of 297 (heroin-dependent subjects and controls) had the 10/10 genotype of the 
3’ VNTR of DAT gene (Table 7a). It can be seen that the 10 allele of DAT gene is the 
most common allele, this was also reported in other studies (Nakatome et al., 1995; 
Gelemter et a l , 1998; Lerman et al” 1999). However, around 90% of our participants 
had at least one 10 allele, resulting in a very skewed distribution. Therefore analyses 
of 3，VNTR of DAT gene were based on the presence or absence of the next common 
allele, the 9 allele. The 9 allele was more frequent in heroin-dependent subjects than 
in controls. Nevertheless, there was no significant difference in genotype frequency 
(p=0.519) nor allelic frequency (p=0.351) for the association between the 3，VNTR 
polymorphism of DAT gene and heroin dependence. 
The 9 allele has been shown to be present more frequently in cocaine abusers who 
reported paranoid ideation with cocaine use (Gelemter et al., 1994). A linkage 
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between the DAT gene and bipolar disorder has been reported (Kelsoe et al” 1996). In 
addition, opposite abnormalities of DAT density in violent and nonviolent alcoholics 
were observed (Tiihonen et al.’ 1995). This implies that differences in the expression 
of the genotype may account for the phenotypic variation in personality traits of 
addicts (Schmidt et al” 1998). In the present study, although no association between 
the 3，VNTR polymorphism of the DAT gene and heroin dependence were found, one 
cannot rule out that this gene may still exert some indirect influence on a subject's 
vulnerability to heroin dependence through a variation in personality traits. 
Since the chronic treatment of rats with morphine significantly decreases the DAT 
density in NAc (Simantov 1993), it was believed that DAT gene may participated in 
the heroin dependence. However, the 9 allele is in the 3’ untranslated region of the 
DAT gene. It is unlikely that a polymorphism in the 3，untranslated region will alter 
the gene expression or protein structure of DAT. Thus, it may be in linkage 
disequilibrium with a mutation close to it. Variable results in population-based 
association studies of 3’ VNTR polymorphism of the DAT gene may partly be due to 
unappreciated population differences in the frequencies of alleles. For instance, the 7 
allele of 3' VNTR polymorphism of the DAT gene is more frequent in alcoholics who 
are heterozygous for the inactive aldehyde dehydrogenase-2 allele (ALDH2*2) in the 
Japanese population (Muramatsu and Higuchi, 1995). However, only 1% of this 
polymorphism was found in our Chinese participants. Therefore, although a 
significant association between the 9 allele of the DAT gene and heroin dependence 
was not be found in the present study, it remains to be determined whether such an 
association may be found in other ethnic populations. 
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Taql A Polymorphism of DRD2 Gene 
DRD2, another candidate gene in the dopaminergic system, has been investigated 
extensively by many investigators. The Al allele of the DRD2 gene has been 
correlated with increased risk of severe alcoholism (Blum et al., 1991; Amadeo et 
al.,1993; Arinami et al., 1993; Noble et al, 1994; Ban et al., 2000; Markianos et al, 
2000)，cocaine dependence (Noble et al., 1993; Comings et al., 1994), obesity 
(Comings et al., 1993)，attention deficit hyperactivity disorder (Comings et al , 1991)， 
Tourette syndrome (Comings et al , 1991; Devor, 1992), pathological gambling 
(Comings et al., 1994), smoking (George et al , 1993; Noble et al., 1994; Bierut et al., 
2000), enhanced response to stress (Berman and Noble, 1997), novelty seeking and 
reward (Noble et al , 1998). 
It was reported that the diminished CNS dopaminergic activity in Al allele carriers as 
compared to A2 allele carriers was due to the reduced number of DRD2 (Noble et al., 
1994; Berman and Noble, 1995) instead of the difference in the affinity of DRD2 
between Al and A2 carriers (Noble et al., 1991; Thompson et a l , 1997). Therefore, it 
may be postulated that subjects inheriting the Al allele of DRD2 gene may 
compensate for a deficit in their mesocorticolimbic dopaminergic pathways by the use 
of an agent known to increase brain dopamine levels such as heroin or alcohol (Van 
Ree et al., 1999). The subsequent stimulation by dopamine of Al allelic carriers of 
DRD2 could be strongly reinforcing and the pleasurable and rewarding experience of 
substances of abuse subsequently may increase the risk for addiction. Thus, it was 
speculated that the Al allele of DRD2 maybe the predisposing factor for substance 
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dependence, like heroin dependence. 
However, in the present study, there was no significant difference in genotype 
(p=0.536) nor allelic frequency (p=0.711) for the association between the Taql A 
polymorphism of DRD2 and heroin dependence between the heroin-dependent and 
control groups. Since the Taq I A polymorphism of DRD2 gene is located at the 3’ 
non-coding region. It has been proposed that the most likely explanation for the 
association between Al allele of the DRD2 gene and heroin dependence is that the 
sequence variation causing the Taql A polymorphism is in linkage disequilibrium with 
functional allelic variants that lie at a distance, upstream or even downstream from the 
corresponding coding region (Amadeo et al., 1993). As the Al allele of the DRD2 
gene is associated with a number of disorders, it could reduce the transcriptional 
activity of the DRD2 gene and thus modify addictive behaviour like heroin 
dependence. As a result, it may be possible that the Al allele of the DRD2 gene act as 
a modifying gene rather than as the primary etiological agent (Coinings et al., 1991). 
As fewer than half of the subjects were found to carry the Al allele, it cannot be with 
total conviction that one could state that the heterozygous composition is the cause of 
each disorder. 
Recently, a functional polymorphism in the 5' promoter region of DRD2 gene has 
been identified (-141C INS/Del), which appears to affect susceptibility to 
schizophrenia (Arinami et al., 1997). Thus it encourages further investigation of the 
DRD2 gene to elucidate its role in governing heroin-dependent behaviour. 
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Neil Polymorphism of GABRG2 Gene 
In the present study, a significant association was not be found between the Neil 
polymorphism of the GABRG2 gene and heroin dependence. This may be due to the 
presence of linkage disequilibrium with functional allelic variants in other regions of 
these gene, such as in the promoter, introns or exons. Although little is known about 
the specific role of the GABA A receptor in addictive behaviour (Loh et al., 1999)，it 
was postulated that changes in subunit expression may alter the assembly of GABA A 
receptors which could account for the changes in receptor function and binding 
(Grobin et al., 1998). Subjects who carry the mutated GABA A receptor gene may 
have diminished activation of chloride channel, which in turn affect the intoxicating 
effects of the drug (Noble et al., 1998). Therefore, we have postulated that the activity 
of GABA-mediated chloride channel is reduced in the carriers with GABRG2 variant. 
Consequently, large amounts of heroin may have to be taken, resulting to an 
increasing risk in the development of heroin dependence. The proposed alternation in 
subunit expression may be an endogenous regulatory mechanism controlling the 
activity of GABA A receptors (Grobin et al., 1998). Further studies looking at other 
polymorphic sites at the GABA A receptor gene are welcome to reveal the 
involvement of this receptor in heroin dependence. 
It can be concluded that the G allele of the A118G and C1031G polymorphisms of the 
hMOR gene are both associated with heroin dependence. Moreover, significant 
association were found between the C allele of T921C polymorphism of hDOR gene 
and heroin dependence in the Hong Kong Chinese population. However, so far there 
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is no statistical significant association between heroin dependence and those 
polymorphisms in DAT, DRD2 and GABRG2 genes that were examined in this study. 
It seems that opioid receptor genes such as both hMOR and hDOR genes may be 
genetic risk factors for heroin dependence. However, it is speculated that no single 
gene may be either necessary or sufficient to explain the likelihood of the 
development of addictive behaviour, for instance heroin dependence. It seems from 
the present study that a combination of genes and their interaction may be likely 
involved. It is suggested that the combined genotypes of these opioid receptor genes 
will make the vulnerability of heroin dependence more robust. Thus, each candidate 
gene contributes to a certain extent and the cumulative effects of their functional 
alteration produces a more robust influence. Based on these findings, further study on 
other nearby polymorphic sites is essential because the polymorphisms examined in 
this study may be in linkage disequilibrium with other potential candidate genes. 
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APPENDIX II Table of Severity Ratings 
Client Rating Interyiewewer Severity Final Severity  
~ Rating Range Rating 
‘ ° 0 
0 0 1 2 0 0 1 2 3 1 0 2 3 4 -7 0 3 4 5 3 0 4 5 6 4 0 5 6 7 5 0 6 7 8 6 0 7 8 9 7 
1 0 0 1 0 1 2 0 1 1 2 3 1 1 2 3 4 2 1 3 4 5 3 1 4 5 6 4 1 5 6 7 5 1 6 7 8 6 
1 7 8 9 7 
2 0 0 
2 0 1 2 1 2 1 2 3 2 2 2 3 4 3 2 3 4 5 4 2 4 5 6 5 2 5 6 7 6 
2 6 7 8 7 
I 7 8 9 8 
3 0 0 
3 0 1 2 2 3 1 2 3 3 3 2 3 4 4 3 3 4 5 5 3 4 5 6 6 3 5 6 7 7 3 6 7 8 8 3 7 8 9 9 r ° 0 — 
4 0 1 2 2 4 1 2 3 3 4 2 3 4 4 4 3 4 5 5 : 4 5 6 6 4 5 6 7 7 ! 6 7 8 8 I ‘ 9 
APPENDIX III 
A allele G allele Total 
Hispanic 85.5% 14.2% 
African-American 98.4% 1.6% ^ 
Caucasian 88.5% 11.5% 
Chinese 63.8% 36.2% ^ 
� 
APPENDIX IV 
Single Nucleotide Nucleotide p o s i t i o n C o r r e s p o n d i n g amino a c i d ~ 
Polymorphism change 
hMORAl lSG m Asn -> Asp 
~ h M O R C l O S l G Ser Cys  
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